Euro Health Consumer Index 2016
The Green countries on the map on the front cover are scoring >800 on the 1000-point scale. Red are countries scoring <650.

The minimum possible score is 333.
Contents

EUROPEAN HEALTHCARE SUCCESS CHALLENGES EVALUATION ......................................................... 5

1. SUMMARY .................................................................................................................................. 6
   1.1 GENERAL OBSERVATIONS — EUROPEAN HEALTHCARE IMPROVING ........................................ 6
   1.2 COUNTRY PERFORMANCE .................................................................................................... 6
   1.3 COUNTRY ANALYSIS OF THE 35 COUNTRIES ...................................................................... 8
   1.4 LESS WEALTHY COUNTRIES ON THE RECOVERY FROM FINANCIAL CRISIS? ......................... 21
   1.5 BBB; BISMARCK BEATS BEVERIDGE — NOW A PERMANENT FEATURE ............................. 22

2. INTRODUCTION .......................................................................................................................... 23
   2.1 BACKGROUND ..................................................................................................................... 24
   2.2 INDEX SCOPE ...................................................................................................................... 25
   2.3 ABOUT THE AUTHOR .......................................................................................................... 25

3. RESULTS OF THE EURO HEALTH CONSUMER INDEX 2016 .................................................... 26
   3.1 RESULTS SUMMARY ............................................................................................................. 28

4. BANG-FOR-THE-BUCK ADJUSTED SCORES .............................................................................. 32
   4.1 BFB ADJUSTMENT METHODOLOGY .................................................................................... 32
   4.2 RESULTS IN THE BFB SCORE SHEET ................................................................................ 33

5. TRENDS OVER THE 10 YEARS .................................................................................................. 34
   5.1 SCORE CHANGES 2006 - 2016 ............................................................................................ 34
   5.2 HEALTHCARE QUALITY AS OUTCOMES ........................................................................... 36
   5.3 TRANSPARENT MONITORING OF HEALTHCARE QUALITY ................................................. 38
   5.4 LAYMAN-ADAPTED COMPREHENSIVE INFORMATION ABOUT PHARMACEUTICALS .......... 39
   5.5 WAITING LISTS: A MENTAL CONDITION AFFECTING HEALTHCARE STAFF? ..................... 39
   5.6 WHY DO PATIENTS NOT KNOW? ........................................................................................ 43
   5.7 MRSA SPREAD ...................................................................................................................... 43

6. HOW TO INTERPRET THE INDEX RESULTS? .............................................................................. 44

7. EVOLVEMENT OF THE EURO HEALTH CONSUMER INDEX ..................................................... 45
   7.1 SCOPE AND CONTENT OF EHCI 2005 ................................................................................ 45
   7.2 SCOPE AND CONTENT OF EHCI 2006 – 2014 ................................................................... 45
   7.3 EHCI 2016 ............................................................................................................................ 46
   7.4 INDICATOR AREAS (SUB-DISCIPLINES) ............................................................................. 47
   7.5 SCORING IN THE EHCI 2016 ............................................................................................. 47
   7.6 WEIGHT COEFFICIENTS ..................................................................................................... 48
   7.7 INDICATOR DEFINITIONS AND DATA SOURCES FOR THE EHCI 2016 .............................. 50
   7.8 THRESHOLD VALUE SETTINGS ........................................................................................... 56
   7.9 “CUTS” DATA SOURCES .................................................................................................... 57
   7.10 CONTENT OF INDICATORS IN THE EHCI 2016 ............................................................... 58
   7.11 EXTERNAL EXPERT REFERENCE PANEL ......................................................................... 58

8. REFERENCES ................................................................................................................................ 99
   8.1 MAIN SOURCES .................................................................................................................... 99

APPENDIX 1. THE TRUE SAGA ABOUT WERNER’S HIP JOINT, OR WHAT WAITING TIMES SHOULD BE IN ANY HEALTHCARE SYSTEM .................................................................................................................. 100
European healthcare success challenges evaluation

In times of pessimism and disillusion there is a need for functions of society which work and deliver. In Europe, healthcare is such an asset. It gets better with every year, saving lives, curing disease and strengthening quality of life among the public. And, in the era of Trumpism, largely, it is affordable to almost all Europeans.

This is not the same as claiming that everybody gets the care they need or that healthcare is a well-oiled, faultless wonder. But as the Euro Health Consumer Index (EHCI) has shown for more than ten years, the publicly funded healthcare systems of Europe have steadily improved. The Index scale is a way to measure to what extent each one of the 35 countries meet expectations of good, consumer-friendly healthcare. In the 2008 EHCI the champion country scored 84 %; 2016 the winner scores no less than 93 %, with 11 countries scoring above 80 %. In the low end there is a similar development, from the 45 to 50 percent score level (meaning, sadly, that the performance gap between old and newer EU members remain). The whole block of 35 countries advances.

In the Index report there are numerous examples of the successful improvement of systems performance. There is great potential of further progress, at least if mutual cross-border learning potential accelerates:

- What would it mean to shorter waiting, cost of queuing and personal inconvenience if many more countries offered the same prompt access to care as Belgium or the FYR Macedonia?

- With prevention still a largely unexploited resource for better health and care, imagine if Norway, the leader in this EHCI sub-discipline, could set the standard to copy and implement around our continent?

- As more and more countries get close to reaching the Index ceiling for treatment outcomes it seems that not only big spenders but as well medium wealth countries such as Finland, Iceland, the Czech Republic and Slovenia have found cost-efficient solutions for inspiration.

Value-for-money health systems are in the international searchlight. What will be affordable and sustainable to countries with aging populations, funding deficits and shortage of workforce? This is a tough nut to crack to national governments as well as to the European Commission and the OECD. We dare say that there is today enough knowledge to repair failing systems - but is there enough determination?

The ongoing progress of performance requires not only a more challenging scoreboard but as well a new approach re. what indicators can grasp the full potential of modern healthcare. The EHCI (and additional HCP measurements) will have to develop with the changing face of healthcare. 2017 will be the year of re-designing the EHCI. Read more about this process on www.healthpowerhouse.com – and welcome to tell us how you think we ought to proceed!

Johan Hjertqvist
HCP Founder & President

The EHCI 2016 was produced with no outside financial support, i.e. 100% of the costs were borne by the Health Consumer Powerhouse, Ltd.
1. Summary

The Euro Health Consumer Index 2016 is only a partial update of the 2015 edition. This is for two main reasons:

A) The EHCI 2016 has been produced with no external financial support, i.e. with the expense covered entirely by the Health Consumer Powerhouse.

B) The continuous improvement of healthcare service performance (also right through the "financial crisis" triggered in 2008) has made some indicators and or score cut-off values obsolete and/or indistinctive.

In spite of financial crisis-induced austerity measures, such as the much publicized restrictions on the increase of healthcare spend, European healthcare keeps producing better results. Survival rates of heart disease, stroke and cancer are all increasing, even though there is much talk about worsening lifestyle factors such as obesity, junk food consumption and sedentary life. Infant mortality, perhaps the most descriptive single indicator, also keeps going down, and this can be observed also in countries such as the Baltic states, which were severely affected by the financial crisis.

This means that the next EHCI edition will have to sacrifice longitudinal analysis, by doing a combination of inventing a number of new, more challenging indicators, and by raising the cut-off limits between Red/Yellow/Green scores:

“Internet pharmacopoeias” existed in only two countries (Sweden and Denmark) when the EHCI was started – today, almost every country has them. Infant mortality when first introduced had 9 countries scoring Green – today, 24 countries do that, with the same limit of less than 4 deaths per 1000 births for a Green. Similar observations can be made for many indicators.

1.1 General observations – European healthcare improving

11 countries (up from 8 in 2015), all Western European, are scoring above 800 points of the maximum 1000. The first CEE country, the Czech Republic, keeps closing in, now only 6 points behind Sweden in 12th place.

1.1.1 Why is there no correlation between accessibility to healthcare and money spent?

Answer: Because it is inherently cheaper to run a healthcare system without waiting lists than having waiting lists! Contrary to popular belief, not least among healthcare politicians, waiting lists do not save money – they cost money!

Healthcare is basically a process industry. As any professional manager from such an industry would know, smooth procedures with a minimum of pause or interruption is key to keeping costs low!

1.2 Country performance

The EHCI 2016 total ranking of healthcare systems shows The Netherlands holding out against the onslaught of Switzerland; the Swiss 904 points would have meant a very comfortable victory in the EHCI as late as 2014. However, the Netherlands, in 2015
breaking the 900-point barrier for the first time in the EHCI, is clinging on to the top position by scoring 927 points!

The changes in rank should not at all be dismissed as an effect of changing indicators, of which there are 48 in the EHCI 2016, the same indicators as in the previous year. The Netherlands is the only country which has consistently been among the top three in the total ranking of any European Index the Health Consumer Powerhouse (HCP) has published since 2005. The Netherlands is sub-discipline winner, or joint winner, in three of the six sub-disciplines of the EHCI 2016. The Dutch healthcare system does not seem to have any really weak spots, by 2016 having made improvement regarding the waiting times situation, where some central European states excel. Normally, the HCP takes care to state that the EHCI is limited to measuring the “consumer friendliness” of healthcare systems, i.e. does not claim to measure which European state has the best healthcare system across the board.

However, the fact that it seems very difficult to build an Index of the HCP type without ending up with The Netherlands on the medallists’ podium, creates a strong temptation to actually claim that the winner of the EHCI 2016 could indeed be said to have “the best healthcare system in Europe”. There should be a lot to learn from looking deeply into the Dutch progress!

Switzerland has for a long time had a reputation for having an excellent, although expensive, healthcare system, and it therefore comes as no surprise that the more profound research which eliminated most n.a. scores results in a prominent position in the EHCI.

Bronze medallists are Norway at 865 points; the very high per capita spend on healthcare services finally paying off, but losing most points on their totally inexplicable waiting list situation!

Belgium (4th, 860 points) seems to have got its act together on Outcomes quality and monitoring/reporting of results, which in combination with what might be the best accessibility to healthcare services anywhere in Europe

Denmark (9th, 827 points, which is 34 points more than was good for the same rank in 2015!) did gain a lot from the introduction of e-Health indicators. None the less, as can been seen from the longitudinal analysis in Chapter 5.1, Denmark has been on a continuous rise since it was first included in the EHCI 2006, until competition tightened in 2014, and Denmark reduced access to Outcomes information and tightened the rules for patient access to caregivers.

The Swedish score for technically excellent healthcare services is, as ever, dragged down by the seemingly never-ending story of access/waiting time problems, in spite of national efforts such as Vårdgaranti (National Guaranteed Access to Healthcare); in 2016, Sweden drops back to 12th place with 786 points, which were enough for 10th place a year ago. Like most points lost (125 points less than Belgium or Switzerland) is on Accessibility, where Sweden, Ireland and Poland have the lowest score among the 35 countries.

Portugal, 14th at 763 points, squeezes past the U.K. by a narrow margin – well done!

In southern Europe, Spain and Italy provide healthcare services where medical excellence can be found in many places. Real excellence in southern European healthcare seems to be a bit too much dependent on the consumers' ability to afford private healthcare as a supplement to public healthcare. Also, both Spain and Italy show large regional variation which tends to result in a lot of Yellow scores for these countries.
Some eastern European EU member systems are doing surprisingly well, particularly the Czech Republic, Slovenia and Estonia, considering their much smaller healthcare spend in Purchasing Power Parity (PPP) adjusted dollars per capita.

In 2014, the FYR Macedonia made the most remarkable advance in the EHCI scoring of any country in the history of the Index, from 27th to 16th place, largely due to more or less eliminating waiting lists by implementing their real time e-Booking system! This situation seems to be sustainable in 2016, with a small drop to 20th place as other countries improve.

1.3 Country analysis of the 35 countries

1.3.1 The Netherlands!!!

The Netherlands is the only country which has consistently been among the top three in the total ranking of any European Index the Health Consumer Powerhouse has published since 2005. The 2012 NL score of 872 points was by far the highest ever seen in a HCP Index. The 927 points in 2016 are even more impressive, and underlines that the EHCI 2017 will have to be more challenging in order to register differences.

The Netherlands have also scored 922 points in the Euro Diabetes Index 2014. That score would normally have been a secure Gold medal – in the EDI, that was seized by Sweden at 936 points on the power of having data on all indicators.

The NL wins four of the six sub-disciplines of the Index, and the large victory margin seems essentially be due to that the Dutch healthcare system does not seem to have any really weak spots, except possibly some scope for improvement regarding the waiting times situation, where some central European countries excel.

Normally, the HCP takes care to state that the EHCI is limited to measuring the "consumer friendliness" of healthcare systems, i.e. does not claim to measure which European state has the best healthcare system across the board.

Counting from 2006, the HCP has produced not only the generalist Index EHCI, but also specialist Indexes on Diabetes, Cardiac Care, HIV, Headache and Hepatitis. The Netherlands are unique as the only country consistently appearing among the top 3 – 4, regardless what aspects of healthcare which are studied. This creates a strong temptation to actually claim that the landslide winner of the EHCI 2016 could indeed be said to have “the best healthcare system in Europe”.

1.3.1.1 So what are the Dutch doing right?

It has to be emphasized that the following discussion does contain a substantial amount of speculation outside of what can actually be derived from the EHCI scores:

The NL is characterized by a multitude of health insurance providers acting in competition, and being separate from caregivers/hospitals. Also, the NL probably has the best and most structured arrangement for patient organisation participation in healthcare decision and policymaking in Europe.

Also, the Dutch healthcare system has addressed one of its few traditional weak spots, Accessibility, by setting up 160 primary care centres which have open surgeries 24 hours a day, 7 days a week. Given the small size of the country, this should put an open clinic within easy reach for anybody.

Here comes the speculation: one important net effect of the NL healthcare system structure would be that healthcare operative decisions are taken, to an unusually high degree, by medical professionals with patient co-participation. Financing agencies and
healthcare amateurs such as politicians and bureaucrats seem farther removed from operative healthcare decisions in the NL than in almost any other European country. This could in itself be a major reason behind the NL victory in the EHCI 2008 – 2016.

1.3.1.2 So what, if anything, are the Dutch doing wrong?

The NL scores well or very well in all sub-disciplines, except possibly Accessibility and Prevention, where the score is more mediocre – on the other hand, so are those of most other countries.

The “traditional” Dutch problem of mediocre scores for Waiting times has to a great extent been rectified by 2016. As was observed by Siciliani & Hurst of the OECD in 2003/2004, and in the EHCI 2005 – 2016, waiting lists for specialist treatment, paradoxically, exist mainly in countries having “GP gatekeeping” (the requirement of a referral from a primary care doctor to see a specialist).

GP gatekeeping, a “cornerstone of the Dutch healthcare system” (said to the HCP by a former Dutch Minister of Health and repeated in the Dutch parliament November 2014) is widely believed to save costs, as well as providing a continuum of care, which is certainly beneficial to the patient. As can be seen from the references given in Section 7.10.2 on indicator 2.2, there is no evidence to support the cost-reducing hypothesis. Also, as can be seen in Section 4.1, the NL has risen in healthcare spend to actually having the highest per capita spend in Europe, by 2014 close to what the HCP internally calls “the three rich bastards”; Norway, Switzerland and Luxembourg, who have a GDP per capita in a class of their own. This was observed already in the EHCI 2009.

By 2014, The Netherlands are at par with Sweden and Germany for healthcare spend!

This has been extensively treated in the EHCI 2013 report.

The Dutch healthcare system is characterised by over-use of in-patient care (and institutionalised psychiatric care and elderly care.

It seems that actual modes of operating the healthcare system in The Netherlands could explain the high per capita healthcare spend, i.e. not the multi-payor model. If the country can afford this, fine; but also for Outcomes and patient quality of life reasons, a programme to reduce the share of in-patient care would be beneficial for the Dutch healthcare budget! According to Dutch government sources, and presented at the Irish Health Summit in May 2016, there is a strategy aimed at saving GEUR 12/year by switching to less in-patient care.

1.3.2 Switzerland

Silver medallists, 904 points (up from 894).

Switzerland has enjoyed a solid reputation for excellence in healthcare for a long time. Therefore it is not surprising that when the n.a.’s of previous EHCI editions have mainly been eliminated, Switzerland scores high. Considering the very respectable money ploughed into the Swiss healthcare system, it should! Along with Belgium, and now the FYR Macedonia, the only country to score All Green on Accessibility.

In 2016, Switzerland is outdistancing a “hornets’ nest” of other Western European Countries scoring above 800 points! Swiss healthcare has probably been this good also before; the highly decentralised cantonal structure of the country has made data collection difficult.

1.3.3 Norway

3rd place, 865 points. Norwegian wealth and very high *per capita* spend on healthcare seem to be paying off – Norway has been slowly but steadily rising in the EHCI ranking over the years. Traditionally, Norwegian patients complained about waiting times. This has subsided significantly, but is still where Norway loses most of the points missing: -87 points compared with class leaders Belgium and Switzerland!

The poor accessibility of Norwegian healthcare must be more or less entirely attributed to mismanagement, as lack of resources cannot possibly be the problem. The fact that it is *cheaper* to operate a healthcare system without waiting lists (*i.e.* waiting lists do not save money, the *cost* money) could actually explain the Norwegian situation. Too much money can be a curse, hindering rationalization or the learning of efficient logistics.

1.3.4 Belgium

Perhaps the most generous healthcare system in Europe seems to have got its quality and data reporting acts together, and ranks 4th in the EHCI 2016 (860 points). Still not quite top class on medical treatment results (“Outcomes”).

1.3.5 Iceland

Due to its location in the North Atlantic, Iceland (5th, 854 points) has been forced to build a system of healthcare services, which has the capability (not dimensions!) of a system serving a couple of million people, which is serving only 300 000 Icelanders. Iceland belongs to the group of five countries scoring 288 on Outcomes, which is as close to a perfect 300 as is possible to get without reaching it.

It also seems that all speculation about the financial crisis affecting Icelandic healthcare has been exaggerated. Basically, Iceland is a very wealthy country, which is also proved by the speedy recovery from the crisis.

Lacking its own specialist qualification training for doctors, Iceland does probably benefit from a system, which resembles the medieval rules for carpenters and masons: for a number of years after qualification, these craftsmen were forbidden to settle down, and forced to spend a number of years wandering around working for different builders. Naturally, they did learn a lot of different skills along the way. Young Icelandic doctors generally spend 8 – 10 years after graduation working in another country, and then frequently come back (and they do not need to marry a master builder’s widow to set up shop!). Not only do they learn a lot – they also get good contacts useful for complicated cases: the Icelandic doctor faced with a case not possible to handle in Iceland, typically picks up the phone and calls his/her ex-boss, or a skilled colleague, at a well-respected hospital abroad and asks: Could you take this patient?, and frequently gets the reply: “Put her on a plane!”

1.3.6 Luxembourg

Luxembourg (6th, 851 points), being the wealthiest country in the EU, could afford to build its own comprehensive healthcare system. Unlike Iceland, Luxembourg has been able to capitalize on its central location in Europe. With a level of common sense which is unusual in the in-sourcing-prone public sector, Luxembourg has not done this, and has for a long time allowed its citizens to seek care in neighbouring countries. It seems that they do seek care in good hospitals. Probably for this reason, Luxembourg loses

---

2 Some would say over-generous: a personal friend of the HCP team, living in Brussels, was “kidnapped and held” in hospital for 6 days(!) after suffering a vague chest pain one morning at work.
points on the Abortions indicator – for reasons of discretion, many LUX women probably has that done outside of the small and intimate Duchy.

The HCP has received some protest from LUX about the bad score on cigarette consumption, on the argument that most of those cigarettes are smoked by other nationalities. From a European public health standpoint, peddling cheap fags to your neighbours is no better than smoking them all yourself.

### 1.3.7 Germany

Germany (7th, 849 points) took a sharp dive in the EHCI 2012, sliding in the ranking from 6th (2009) to 14th. As was hypothesised in the EHCI 2012 report, when patient organisations were surprisingly negative, this could have been an artefact created by “German propensity for grumbling”, i.e. that the actual deterioration of the traditionally excellent accessibility to health care was less severe than what the public thought, and the negative responses were an artefact of shock at “everything not being free anymore”.

The 2015 survey results seem to confirm this theory, and it would appear that German patients have discovered that “things are not so bad after all”, with Mrs. Merkel ruling as Queen of Europe.

Germany has traditionally had what could be described as the most restriction-free and consumer-oriented healthcare system in Europe, with patients allowed to seek almost any type of care they wish whenever they want it (“stronger on quantity than on quality”). The traditional weakness of the German healthcare system: a large number of rather small general hospitals, not specializing, resulting in mediocre scores on treatment quality, seems to be improving – a tendency even more prominent in 2016, when Germany is one of the six countries sharing the highest score on Outcomes.

In a feedback round from national healthcare bodies, the response from the German Bundesministerium für Gesundheit (BMG) contained an interesting reference to a study of waiting times in German primary care. It is irrelevant what the actual numbers were in that study; the unit of time used to measure and analyse primary care accessibility was not months, weeks or days, but minutes!

### 1.3.8 Finland

8th, 842 points. As the EHCI ranking indicates, Finland has established itself among the European champions, with top Outcomes at a fairly low cost. In fact, Finland is a leader in value-for-money healthcare.

Some waiting times are still long, provision of “comfort care” such as cataract surgery and dental care is limited and that out of pocket-payment, also for prescription drugs, is significantly higher than for Nordic neighbours.

This probably means that the public payors and politicians traditionally were less sensitive to “care consumerism” than in other affluent countries. This situation seems to have been put right in recent years, with Finland being among the top scorers for Range and Reach of Healthcare Services.

### 1.3.9 Denmark

9th place, 826 points. Denmark was catapulted into 2nd place by the introduction of the e-Health sub-discipline in the EHCI 2008. Denmark was in a continuous rise since first included in the EHCI 2006. Interestingly, when the EHCI 2012 was reverted to the EHCI 2007 structure, Denmark survived this with flying colours and retained the silver medal with 822 points! Denmark has also made dramatic advancement in the reduction of
heart disease mortality in recent years. Denmark was one of only three countries scoring on “Free choice of caregiver in the EU” after the criteria were tightened to match the EU directive, and also on having a hospital registry on the Internet showing which hospitals have the best medical results.

However, in 2013, the introduction of the Prevention sub-discipline did not help Denmark, which lost 20 points on this sub-discipline relative to aggressive competitors. Although the causality is hard to prove, that Danish score drop did coincide in time not only with the removal of Outcomes data from its hospital quality information system. It also coincided with the tightening of access to healthcare, with only two telephone numbers being available to Danish patients; the number of their GP, or the emergency number 112!

1.3.10 Austria
Austria (10th, 826 points) suffered a drop in rank in 2012.

In 2016, Austria makes a comeback among the top countries, which score >800 points. The introduction of the Abortion indicator does not help: Austria does not have the ban on abortion found in Poland and three more countries, but abortion is not carried out in the public healthcare system. Whether Austria should deserve a Red or an n.a. score on this indicator could be a matter of discussion – there are no official abortion statistics.

1.3.11 France
815 points. Dropped out of the top 10 after reducing formerly liberal access to specialist services around 2009. Otherwise a technically competent and efficient system, with a tendency to medicalize a lot of conditions³, and to give patients a lot of drugs!

France has long had the lowest heart disease mortality in Europe, and was the first country (1988), where CVD was no longer the biggest cause of death. Also, France was #1 in the recently published Euro Heart Index 2016⁴.

1.3.12 Sweden
Sweden tumbled in the EHCI 2013 from 6th place to 11th at 756 points, which was only 6 points down from the 2012 value of 762 points. In the EHCI 2016, Sweden drops further to #12, at the same 786 points as in 2015. In 2016, with 11 countries scoring above 800, the seemingly never-ending Swedish problems with healthcare waiting lists sends the country out of this top group.

Sweden scores surprisingly well in the sub-discipline Prevention, considering that the country’s healthcare system has a long tradition of steering patients away from taking up time for their doctor unless really sick.

Sweden enjoys the companionship only of a number of CEE countries having more than 30 abortions per 100 live births, which in CEE probably is a remnant from before 1990. In Russia, abortion is still used as a common contraceptive, with 55 abortions per 100 births (and that is down from >200 in the early 1990’s).

At the same time, the notoriously poor Swedish accessibility situation seems very difficult to rectify, in spite of state government efforts to stimulate the decentralized county-operated healthcare system to shorten waiting lists by throwing money at the problem (“Queue-billions”). Sweden now has the highest healthcare spend per capita,  

³ Wadham, Lucy; *The Secret Life of France*, Faber Faber, 2013.
(after the three super-wealthy countries, see Section 4.1) together with The Netherlands and Austria. “Throwing money at a problem” is obviously not an effective way of problem-solving. The HCP survey to patient organizations confirms the picture obtained from the official source www.vantetider.se, that the targets for maximum waiting times, which on a European scale are very modest, are not really met. The target for maximum wait in Sweden to see your primary care doctor (no more than 7 days) is underachieved only by Portugal, where the corresponding figure is < 15 days. In the HCP survey, Swedish and Irish patients paint the most negative pictures of accessibility of any nation in Europe. Particularly cancer care waits, not least in the capital Stockholm, seem inhumane!

Another way of expressing the vital question: Why can FYR Macedonia reduce its waiting times to practically zero, and Sweden cannot?

1.3.13 The Czech Republic

The Czech Republic has always been the star performer among CEE countries, and in 2016 remains at #13 (780 points), only 6 points behind Sweden and leading the group of CEE countries, squeezing ahead of the United Kingdom. Good for accessibility to healthcare services!

1.3.14 Portugal

14th; 763 points (and ahead of the UK). A very impressive climb: In 2013, 16th place on 671 points (up from 25th place in 2012). In 2014, Portugal advanced to 13th place with 722 points. There was a small setback in 2015, mainly due to patients being less positive about waiting times, resulting in a score of 691 points and 20th place (in the middle of the ranking, a small score change can result in dramatic ranking change). Does well in the Bang-for-the-Buck analysis!

1.3.15 United Kingdom

15th place, 761 points. A 2014 survey to the public of the UK, asking about “What is the essence of being British?” got the most common response “Having access to the NHS”. Nevertheless, the UK healthcare system has never made it into the top 10 of the EHCI, mainly due to poor accessibility (together with Poland and Sweden the worst among European healthcare systems) and an autocratic top-down management culture.

Mediocre Outcomes of the British healthcare system are improving, with the UK scoring Green on Infant Mortality for the first time in the EHCI.

The country, which once created the Bletchley Park code-breaking institution would do well to study the style of management of professional specialists created there!

1.3.16 Slovenia

16th place, 740 points.

When the HCP team first visited the Slovenian Ministry of Health in 2006, the MoH representatives proudly stated “We are not a Balkan state – we are an Austrian province, which had bad luck in 1918!”

Slovenia has a GDP/capita which is 3 – 4 times that of the other ex-Yugoslav countries (except Croatia at ~75% of the Slovenian GDP). This difference was not created in just

---

over two decades – in 1985, Croatia and Slovenia together produced 75% of the GDP of Yugoslavia!

With a population of only 2 million people, it sometimes takes only a limited number of skilled and dedicated professionals to make a difference in certain medical specialities. This has been observed in hepatitis, where Slovenia ranked #2 in Europe in the 2012 Euro Hepatitis Index\(^6\), and also in diabetes and CVD, Slovenia ranking #6 in the 2014 Euro Diabetes Index\(^7\) and 5\(^\text{th}\) in the Euro Heart Index 2016\(^4\).

1.3.17 Estonia

729 points. Not exceptional on any of the sub-disciplines, Estonia has done well in the EHCI for a number of years, not least in the context of the quite limited economic resources of this small country. Leader in the Bang-for-the-Buck adjusted Index (see Chapter 4). One of very few countries managing to keep resistant infection rates low – restrictive antibiotics prescribing?

1.3.18 Spain

709 points. Very regionally decentralised. Spanish healthcare seems to rely a bit too much on seeking private care for real excellence; however, Spain is doing better on the Outcomes indicators in 2016 than historically.

1.3.19 Croatia

19\(^\text{th}\) place, 703 points, which is essentially at level with 2015, but results in a minor drop in rank. Croatia (and even more Slovenia) were the remarkable success stories among the ex-Yugoslavian countries, until the Macedonian wonder in 2014. In spite of a GDP/capita, which is still modest by Western European standards, Croatian healthcare does excel also at advanced and costly procedures such a kidney transplants: the Croatian number of 50 transplants per million population is among the top countries of Europe.

1.3.20 Former Yugoslav Republic Of Macedonia (FYROM)

FYROM was the absolute “Rocket of the Year” in 2014, ranking 16\(^\text{th}\) with a score of 700 points, up from 555 points and 27\(^\text{th}\) place in 2013. This also makes the country the “EHCI Rocket of all Time”; no country ever gained 11 positions in the ranking in only one year!

It keeps its score in 2016 with 699 points, giving 20\(^\text{th}\) place.

The country has made a remarkable breakthrough in electronic booking of appointments – since July 2013, any GP can call up the booking situation of any specialist or heavy diagnostic equipment in the country in Real Time with the patient sitting in the room, and book anywhere in the country with a few mouse clicks. This has essentially eliminated waiting times, provided that the patient is willing to travel a short distance (the entire country measures approximately 200 km by 130, with the capital Skopje located fairly centrally). It seems that patients have caught on, with FYROM receiving top scores for accessibility.


Much of this can probably be attributed to firm leadership, with the Minister of Health declaring “I want that system up and running on July 1, 2013; basta! The system ("IZIS") also includes e-Prescriptions.

The FYROM IZIS system is well worth a study trip from other countries! The message to all other European ministers and other persons in charge of healthcare systems: “Go and do likewise.” This advice does not exclude that e-health implementation most often may need some time to settle and that down-sides can occur over time, before patients get used to their newborn power and choice.

The area, where FYROM still has a way to go is on actual medical treatment results. There is no quick fix for this; even with very determined leadership, it will probably be a matter of ~5 years to produce significant improvement.

1.3.21 Ireland

21st place, 689 points.

Ireland has detailed official statistics on waiting times all over healthcare, and that data was been allowed to prevail up until EHCI 2013. However, for several EHCI years, Irish patient organisations have been radically more pessimistic in their responses to the survey conducted as part of EHCI research. It is well known that customers/patients have long memories for less good things. As the same pessimistic results reoccurred in 2016 – Ireland, the UK and Sweden had the worst patient organisation feedback on Accessibility among the 35 countries – doubts must be raised on the validity of official statistics.

As a matter of principle, in the EHCI 2014 – 2016 it has been decided to use the patient organisation feedback to score Ireland on Accessibility. This accounts for the drop from rank 14 to 22 in 2014, with a slight recovery in 2016.

Unfortunately, this was confirmed by the Irish HSE and MoH after the release of the EHCI 2015 report, when they said in a memo that the programme initiated to reduce healthcare waiting times in Ireland aims at a target of no more than 18 months’ (!) wait for a specialist appointment. Even if and when that target is reached, it will still be the worst waiting time situation in Europe.

The fact that Ireland has the highest % of population (> 40 %; down from 52 % three years ago) purchasing duplicate healthcare insurance also presents a problem: should that be regarded as an extreme case of dissatisfaction with the public system, or simply as a technical solution for progressive taxation?

Ireland no longer has a total ban on abortion. The requirement that a woman wishing an abortion becomes subject to judgement on if the pregnancy should be regarded as a serious health hazard, including suicide risk, is a very minor step indeed towards abortion as a women’s right, hence the purple score on this indicator.

1.3.22 Italy

682 points. Italy has the largest internal difference of GDP/capita between regions of any European country; the GDP of the poorest region is only 1/3 of that of Lombardy (the richest). Although in theory the entire healthcare system operates under one central ministry of health, the national Index score of Italy is a mix of Northern Italian and Rome Green scores, and Southern Italian Red scores, resulting in a lot of Yellows.

---

8 Luke 10:37
1.3.23 Slovakia

678 points, up 25 since 2015, which is required just to hang on in the ranking. The fairly recent Slovakian system of private (additional) healthcare insurance has not yet produced a significant change in the EHCI scores.

1.3.24 Serbia

24th place, 670 points, up 116 points since 2015, which makes Serbia the “climber of the year”!

After Serbia’s first inclusion in the EHCI in 2012 (finishing last), there were some very strong reactions from the Ministry of Health in Belgrade, claiming that the scores were unfair. Interestingly, there also were reactions from organisations of medical professionals in Serbia claiming that the Serbian scores were inflated, and that the EHCI did not take corruption in healthcare systems seriously enough. The only directly corruption-related indicator is Under-the-table payments to doctors, where Serbia does score Red.

The major part of the impressive climb is the effect on Waiting Times by licensing and implementing the Macedonian IZIS system for direct specialist care booking, plus e-Prescriptions. Serbia being a larger country than FYROM, the full effect has not materialized fully by the time of EHCI 2016 publication.

There is also anecdotal evidence that corruption, which has long been a plight of the Serbian healthcare system, is being significantly reduced. Unfortunately, not yet to warrant an improved score on this indicator.

1.3.25 Malta

666 points. Up from 663 points in 2015. Decent accessibility, but not too strong on treatment results. Also, there seem to be gaps in the public subsidy system of Maltese healthcare. This is particularly prominent for drug subsidies; many Maltese do not bother with receiving a subsidy. The result is that Malta has little data on drug use!

1.3.26 Cyprus

623 points, up 28 points since 2015. Very difficult to score in the EHCI, as Cyprus does not really have a public healthcare system in the general European meaning. As the EHCI normally does not reward a country for such services obtained by paying privately, it is possible that the score in reality should be lower.

1.3.27 Lithuania

620 points. In 2015, Lithuania recovered from the nosedive to 510 points and #32, which the country took in 2014. This shows that the EHCI can sometimes be sensitive to small changes in responses from the often limited number of patient organisations responding to the HCP survey. In 2016, Lithuania is almost back on its long time trend (see Figure 5.1).

1.3.28 Greece

Greece was reporting a dramatic decline in healthcare spend per capita: down 28% between 2009 and 2011, but a 1% increase in 2012! This is a totally unique number for Europe; also in countries which are recognized as having been hit by the financial crisis, such as Portugal, Ireland, Spain, Italy, Estonia, Latvia, Lithuania etc, no other country has reported a more severe decrease in healthcare spend than a temporary setback in
the order of < 10 % (see Appendix 2). There is probably a certain risk that the 28% decrease is as accurate as the budget numbers, which got Greece into the Euro.

Greece has markedly changed its traditional habit as eager and early adopter of novel pharmaceuticals to become much more restrictive. However, the graph below shows that as late as 2012, Greece still had the 3rd highest \textit{per capita} consumption of pharmaceuticals in Europe, counted in monetary value! Part of the explanation for this is unwillingness to accept generic drugs. It would seem that pharmacists (and doctors?) are not keen on communicating to patients that generics are equal to the branded drugs.

What has partially changed in Greece is the readiness to adopt \textit{new} drugs. As Indicator 6.5 (new arthritis medication) shows, Greece has in some cases radically changed its previous generous attitude to the introduction of novel, expensive pharmaceuticals. Also, the position of Greece in the drug expenses league has dropped from #3 in 2012, to #11 in 2014.

![Graph showing pharmaceutical sales per capita (2014), MEUR p.m.p.](image)

**Figure 1.3.28a.**

Greek pharma expenditure is possibly affected by the fact, that Greece (and Italy) are the two countries in Europe, where the levels of corruption\textsuperscript{10} exceed what could be expected against the poverty level.

Figure 1.3.28b Corruption scores vs. GDP/capita. On the corruption scale, a score of 100 denotes a corruption-free country; the lower the score, the more severe the corruption. There is a quite close correlation (R = 90%) between poverty and corruption. Deviating negatively (i.e. more corrupt than should be expected) are Italy, Greece and Ireland. Very honest, in relation to their economic means, are Estonia and Finland. The three rich countries LUX, CH and NO have been left out – their GDP/capita is 50 – 100% higher than that of any other country.

Greece leads Europe by a wide margin in the number of doctors per capita (below), and also has the highest number of pharmacists per capita. Still the picture of Greek healthcare, painted by the patient organisation responses, does not at all indicate any sort of healthy competition to provide superior healthcare services.
Figure 1.3.28b. Physicians per 100 000 population (broad bars) and Number of doctor appointments per capita (yellow narrow bars).

It would seem almost supernatural that Greece can keep having the large number of doctors and pharmacists, unless these have taken very substantial reduction of income. It deserves to be mentioned that the indicators on Outcomes (treatment results) do not show a worsening of results for Greece.

1.3.29 Latvia

589 points. Being every bit as victimized by the finance crisis as Greece, Latvia together with Lithuania has made a remarkable comeback. Both countries show improvement on the really vital indicator Infant mortality; Latvia has achieved an improvement from 6.2/1000 births (Red score) in 2012 to 3.9/1000 (Green score) in 2014, 3.8 in 2016. This seems sustainable – in a small country, these numbers would be sensitive to random variation.

1.3.30 Hungary and Poland

Hungary (30th at 575 points) and Poland (31st at 564) are two countries, which have not done well in the EHCI in recent years, despite having good and plentiful medical education and a long tradition of solidarity-financed public healthcare. The reason(s) for this is not obvious. However, there could be a common factor between the two countries: It is well known from management practice, that if top management starts focussing on things other than producing the best products or services, the quality of products/services declines. In a corporation, “other things” can be Business For Fun such as “sexy” company acquisitions, using the corporate jet for hunting trips with posh people, or whatever. In recent years, the governments of Hungary and Poland seem to have focussed on things other than the optimal running of the country. In Hungary, things like keeping out 1200 refugees per year – a pathetic number, anyway. In Poland, killing off the free press and banning abortion in all but the most extreme circumstances. Since the start of the EHCI, ongoing political discussions on fundamental reform in Poland (as well as in Romania and other CEE countries) has yet delivered very little. In Hungary, one of the oldest publicly funded CEE healthcare systems has failed to transform from the old Semashko-style mentality into the modern world of patient-centered healthcare. The public and the medical profession of both countries deserve better.

1.3.32 Albania

32nd place, 551 points, up 27 since 2015.

Albania was included in the EHCI at the request of the Albanian Ministry of Health. Albania, as can be seen in Section 4.1, does have very limited healthcare resources. The country avoids ending up last chiefly due to a strong performance on Access, where patient organizations also in 2016 confirmed the official ministry version that waiting times are a minor problem. The ministry explanation for this was that “Albanians are a hardy lot, who only go to the doctor when carried there”, i.e. underutilization of the healthcare system. This is an oversimplification; Albanians visit their primary care doctor more than twice as often as Swedes (3.9 visits per year vs. 1.7)!
Albania shares one problem with all the Balkan states, with some exception for Slovenia: it is difficult to evaluate which healthcare services are accessible without under-the-table payment.

1.3.33 Bulgaria

33rd place, 526 points.

Bulgaria made a remarkable advance between 2012 and 2013 by the power of patient organisations in 2013 giving much more positive responses on survey questions on the EHCI sub-discipline Accessibility. Such an improvement is very difficult to achieve if it is not the result of a system reform such as the FYROM booking/referral system. The HCP team has checked the accuracy of those reports, and they seem to be founded on reality. Unfortunately, Bulgaria loses points on Outcomes and Range & Reach of HC Services.

1.3.34 Montenegro

34th place, 518 points – 34 points up since 2015, enough to avoid last place. One circumstance historically favouring Montenegro was a massive influx of Russian capital, which at the time of writing this report seems to be endangered by the low prices of oil and sanctions against Russian capitalists after the seizure of Crimea.

The country has only 650,000 inhabitants, making it possible for reforms to take effect rapidly.

1.3.35 Romania

35th place, 497 points.

Romania does have severe problems with the management of its entire public sector. In healthcare, discrimination of minority groups such as romani (3½ - 4% of the population) shows as poor Outcomes ratios.

Also, Albania, Romania and Bulgaria are suffering from an antiquated healthcare structure, with a high and costly ratio of in-patient care over out-patient care (see Figure below).
Figure 1.3.35 The higher the share of in-patient care, the more antiquated the healthcare provision structure. If Dutch, Swiss and (possibly) Italians prefer long hospital admissions, they can afford it; Bulgaria, Romania and Albania cannot! They should receive professional support to restructure their healthcare services!

1.4 Less wealthy countries on the recovery from financial crisis?

The overall total scores seem to indicate what could be a macro effect of the financial crisis. The top end of the ranking in 2014 did show a concentration of the wealthier countries, which was more obvious than in any previous edition. It would seem that these countries were able to avoid the (rather modest) effects of the financial crisis, which have affected less affluent countries. This can be interpreted that the financial crisis did result in a slight but noticeable increase of inequity of healthcare services across Europe.

In the total 2016 scores shown in Figure 4.1 below, this equity gap has diminished slightly; the 8 least wealthy countries have gained on average 53 points between 2014 and 2016! This could indicate that also poorer European states are on the recovery from the crisis.

When results are analysed at indicator level, some tendencies seem to be detectable:

1.4.1 Outcomes quality keeps improving

Indicators such as Cancer Survival or Infant Mortality keep showing improvement over time. This is true also for countries such as the Baltic states, which have undergone a financial “steel bath”, in every way comparable with that hit southern Europe or Ireland.
As an example, both Latvia and Lithuania have shown remarkable improvement in Infant Mortality right during the period of the worst austerity measures. This is probably a positive effect of doctors being notoriously difficult to manage – signals from managers and/or politicians are frequently not listened to very attentively. This would be particularly true about providing shoddy medical quality as this would expose doctors to peer criticism, which in most cases is a stronger influencing factor than management or budget signals.

1.4.2 Delays and/or restrictiveness on the introduction of novel pharmaceuticals

As is shown by Indicators 6.3 – 6.5 (section 7.10.6), saving on the introduction/deployment of drugs, particularly novel, patented (expensive) drugs, seems to be a very popular tactic for containing healthcare costs in many countries. This has been observed also in previous HCP Indices\(^\text{11}\).

This is particularly obvious for Greece – a country, which traditionally has been a quick and ready adopter of novel drugs. The Greek public bill for prescription drugs was 8 billion euro as late as 2010, for 11 million people. As a comparison, the Swedish corresponding number was 4 billion euros for 9½ million people – and drug prices have traditionally been lower in Greece. That Greek readiness to introduce new drugs has dropped dramatically, along with the introduction of generic substitution.

Still, the Greek drug consumption by monetary value was the third highest in Europe as late as 2012! By 2014, that had shrunk to be the 11\(^{\text{th}}\) highest.

1.5 BBB; Bismarck Beats Beveridge – now a permanent feature

The Netherlands example seems to be driving home the big, final nail in the coffin of Beveridge healthcare systems, and the lesson is clear: Remove politicians and other amateurs from operative decision-making in what might well be the most complex industry on the face of the Earth: Healthcare! Beveridge systems seem to be operational with good results only in small population countries such as Iceland, Denmark and Norway.

1.5.1 So what are the characteristics of the two system types?

All public healthcare systems share one problem: Which technical solution should be used to funnel typically 8 – 11 % of national income into healthcare services?

**Bismarck** healthcare systems: Systems based on social insurance, where there is a multitude of insurance organisations, Krankenkassen etc, who are organisationally independent of healthcare providers.

**Beveridge** systems: Systems where financing and provision are handled within one organisational system, i.e. financing bodies and providers are wholly or partially within one organisation, such as the NHS of the UK, counties of Nordic states etc.

For more than half a century, particularly since the formation of the British NHS, the largest Beveridge-type system in Europe, there has been intense debating over the relative merits of the two types of system.

Already in the EHCI 2005, the first 12-state pilot attempt, it was observed that “In general, countries which have a long tradition of plurality in healthcare financing and provision, i.e. with a consumer choice between different insurance providers, who in turn do not discriminate between providers who are private for-profit, non-profit or public, show common features not only in the waiting list situation ...”

Looking at the results of the EHCI 2006 – 2016, it is very hard to avoid noticing that the top consists of dedicated Bismarck countries, with the small-population and therefore more easily managed Beveridge systems of the Nordic countries squeezing in. Large Beveridge systems seem to have difficulties at attaining really excellent levels of customer value. The largest Beveridge countries, the U.K., Spain and Italy, keep clinging together in the middle of the Index. There could be (at least) two different explanations for this:

1. Managing a corporation or organisation with 100 000+ employees calls for considerable management skills, which are usually very handsomely rewarded. Managing an organisation such as the English NHS, with close to 1½ million staff, who also make management life difficult by having a professional agenda, which does not necessarily coincide with that of management/administration, would require absolutely world class management. It is doubtful whether public organisations offer the compensation and other incentives required to recruit those managers.

2. In Beveridge organisations, responsible both for financing and provision of healthcare, there would seem to be a risk that the loyalty of politicians and other top decision makers could shift from being primarily to the customer/patient. Primary loyalty could shift in favour of the organisation these decision makers, with justifiable pride, have been building over decades (or possibly to aspects such as the job-creation potential of such organisations in politicians’ home towns).

2. Introduction

The Health Consumer Powerhouse (HCP) has become a centre for visions and action promoting consumer-related healthcare in Europe. “Tomorrow’s health consumer will not accept any traditional borders”, we declared in last year’s report, but it seems that this statement is already becoming true; the 2011 EU Directive for patients’ rights to cross-border care is an excellent example of this trend. In order to become a powerful actor, building the necessary reform pressure from below, the consumer needs access to knowledge to compare health policies, consumer services and quality outcomes. The Euro Health Consumer Indexes are efforts to provide healthcare consumers with such tools. Not only do consumers gain from the transparency of benchmarking, the quality and function of healthcare systems improve as outcomes are displayed and analysed in an open, systematic, and repeated fashion.

This understanding now seems to be shared by the European Commission, during 2016 initiating the formation of an assessment system aimed to identifying successful national health systems. The ultimate purpose is said to be strengthening pan-EU best practices to provide better for value healthcare.
2.1 Background

Since 2004 the HCP has been publishing a wide range of comparative publications on healthcare in various countries. First, the Swedish Health Consumer Index in 2004 (also in an English translation). By ranking the 21 county councils by 12 basic indicators concerning the design of “systems policy”, consumer choice, service level and access to information we introduced benchmarking as an element in consumer empowerment. In two years time this initiative had inspired – or provoked – the Swedish Association of Local Authorities and Regions together with the National Board of Health and Welfare to start a similar ranking, making public comparisons an essential Swedish instrument for change.

For the pan-European indexes in 2005 – 2008, HCP aimed to basically follow the same approach, i.e. selecting a number of indicators describing to what extent the national healthcare systems are “user-friendly”, thus providing a basis for comparing different national systems.

Furthermore, since 2008 the HCP has enlarged the existing benchmarking program considerably:

- In January 2008, the Frontier Centre and HCP released the first Euro-Canada Health Consumer Index, which compared the health care systems in Canada and 29 European countries. The 2009 edition was released in May, 2009.
- The first edition of Canada Health Consumer Index was released in September 2008 in co-operation with Frontier Centre for Public Policy, examining healthcare from the perspective of the consumer at the provincial level, and repeated 2009 and 2010.
- The Euro Consumer Diabetes Index, launched in September 2008, provided the first ranking of European diabetes healthcare services across five key areas: Information, Consumer Rights and Choice; Generosity, Prevention; Access to Procedures and Outcomes. A new edition was published 2014.
- Other Indexes published include the Euro HIV Index 2009, the Euro Headache Index 2012 and the Euro Hepatitis Index 2012.
- This year’s edition of Euro Health Consumer Index covers 48 (+ a COPD mortality indicator) healthcare performance indicators for 35 countries.

Though still a somewhat controversial standpoint, HCP advocates that quality comparisons within the field of healthcare is a true win-win situation. To the consumer, who will have a better platform for informed choice and action. To governments, authorities and providers, the sharpened focus on consumer satisfaction and quality outcomes will support change. To media, the ranking offers clear-cut facts for consumer journalism with some drama into it. This goes not only for evidence of shortcomings and method flaws but also illustrates the potential for improvement. With such a view the EHCI is designed to become an important benchmark system supporting interactive assessment and improvement.

As we heard one of the Ministers of health saying when seeing his country’s preliminary results: “It´s good to have someone still telling you: you could do better.”
2.2 Index scope

The aim has been to select a limited number of indicators, within a definite number of evaluation areas, which in combination can present a telling tale of how the healthcare consumer is being served by the respective systems.

2.3 About the author

Project Management for the EHCI 2016 has been executed by Prof. Arne Björnberg, Ph.D., Chairman of the Health Consumer Powerhouse.

Dr. Björnberg has previous experience from Research Director positions in Swedish industry. His experience includes having served as CEO of the Swedish National Pharmacy Corporation (“Apoteket AB”), Director of Healthcare & Network Solutions for IBM Europe Middle East & Africa, and CEO of the University Hospital of Northern Sweden (“Norrlands Universitetssjukhus”, Umeå).

Dr. Björnberg was also the project manager for the EHCI 2005 – 2015 projects, the Euro Consumer Heart Index 2008 and numerous other Index projects.

Dr. Björnberg is Visiting Professor at the European Center for Peace and Development, a faculty of the United Nations’ University of Peace.
## 3. Results of the Euro Health Consumer Index 2016

### EuroHealth Consumer Index 2016

| Sub-discipline | Indicator                                                                 | Australia | Belgium | Bulgaria | Croatia | Cyprus | Czech Republic | Denmark | Estonia | Finland | France | Germany | Greece | Hungary | Iceland | Italy | Latvia | Lithuania | Luxembourg | Malta | Netherlands | Norway | Poland | Portugal | Romania | Russia | Spain | Sweden | Switzerland | United Kingdom | United States | Total score | Rank |
|----------------|--------------------------------------------------------------------------|-----------|---------|----------|---------|--------|----------------|---------|---------|---------|--------|---------|--------|---------|---------|--------|--------|---------|---------|--------|---------|---------|---------|---------|---------|---------|---------|
| 1. Patient rights and information | 1.1 Healthcare law based on Patients’ Rights | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n

### Sub-discipline weighted score

- **3.1 Decrease of CVD deaths**: 73%
- **3.2 Decrease of stroke deaths**: 80%
- **3.3 Infant deaths**: 83%
- **3.4 Cancer survival**: 85%
- **3.5 Potential Years of Life Lost**: 87%
- **3.6 MRSA infections**: 88%
- **3.7 Abortion rates**: 88%
- **3.8 Depression**: 86%
- **3.9 COPD mortality**: 84%

### 4. Range and reach of services provided

- **4.1 Equity of healthcare systems**: 78%
- **4.2 Cataract operations per 100,000 age group**: 50%
- **4.3 Kidney transplants per million population**: 50%
- **4.4 Free dental care included in the public healthcare offerings**: 50%
- **4.5 Inpatient payments to doctors**: 50%
- **4.6 Long-term care for the elderly**: 50%
- **4.7 % of deaths due to chronic diseases outside of clinic**: 50%
- **4.8 Cancer screening**: 50%

### Sub-discipline weighted score

- **4.1 Inhfluenza vaccination**: 50%
- **4.2 Blood pressure**: 50%
- **4.3 Smoking prevention**: 50%
- **4.4 Alcohol**: 50%
- **4.5 Physical activity**: 50%
- **4.6 HPV vaccination**: 50%
- **4.7 Traffic deaths**: 50%

### 5. Prevention

- **5.1 Rx subsidy**: 50%
- **5.2 Laymen adapted pharmacopoeia**: 50%
- **5.3 Novel cancer drugs deployment rate**: 50%
- **5.4 Access to new drugs (time to subsidy)**: 50%
- **5.5 HIV/AIDS drugs**: 50%
- **5.6 Women's use**: 50%
- **5.7 Antibiotics/supps**: 50%

### Sub-discipline weighted score

- **5.1 Obesity**: 50%
- **5.2 Tobacco**: 50%
- **5.3 Alcohol**: 50%
- **5.4 Anti-smoking campaigns**: 50%
- **5.5 HIV/AIDS drugs**: 50%
- **5.6 Women's use**: 50%
- **5.7 Antibiotics/supps**: 50%

### 6. Pharmaceuticals

- **6.1 Rx subsidy**: 50%
- **6.2 Laymen adapted pharmacopoeia**: 50%
- **6.3 Novel cancer drugs deployment rate**: 50%
- **6.4 Access to new drugs (time to subsidy)**: 50%
- **6.5 HIV/AIDS drugs**: 50%
- **6.6 Women's use**: 50%
- **6.7 Antibiotics/supps**: 50%
# EuroHealth Consumer Index 2016

<table>
<thead>
<tr>
<th>Sub-discipline</th>
<th>Indicator</th>
<th>Italy</th>
<th>Lithuania</th>
<th>Luxembourg</th>
<th>Malta</th>
<th>Montenegro</th>
<th>Netherlands</th>
<th>Norway</th>
<th>Poland</th>
<th>Portugal</th>
<th>Romania</th>
<th>Slovakia</th>
<th>Slovenia</th>
<th>Spain</th>
<th>Sweden</th>
<th>Switzerland</th>
<th>United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Patient rights and information</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 Healthcare bill based on Patients’ Rights</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2 Patient organisations involved in decision making</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.3 No-fault medical malpractice insurance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.4 Right to second opinion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 Access to own medical record</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.6 Registry of base file doctors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.7 View or 24/7 telephone HC info with interactivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.8 Cross-border care seeking financial start issue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.9 Provider catalogue with quality ranking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.10 EPR penetration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.11 Patients’ access to on-line booking of appointments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.12 e-prescription</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-discipline weighted score</td>
<td>83</td>
<td>87</td>
<td>97</td>
<td>101</td>
<td>80</td>
<td>63</td>
<td>122</td>
<td>125</td>
<td>66</td>
<td>108</td>
<td>80</td>
<td>111</td>
<td>97</td>
<td>104</td>
<td>87</td>
<td>104</td>
<td>111</td>
</tr>
<tr>
<td>2. Accessibility (waiting times for treatment)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Daily doctor same day access</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 Direct access to specialist</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.3 Major elective surgery &lt;90 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.4 Cancer therapy &lt; 21 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5 CT scan &lt; 7days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.6 A&amp;E waiting times</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-discipline weighted score</td>
<td>158</td>
<td>113</td>
<td>175</td>
<td>192</td>
<td>200</td>
<td>163</td>
<td>130</td>
<td>100</td>
<td>150</td>
<td>150</td>
<td>188</td>
<td>163</td>
<td>125</td>
<td>113</td>
<td>100</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>3. Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.1 Decrease of CVD deaths</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.2 Decrease of stroke deaths</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3 Infant deaths</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.4 Cancer survival</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.5 Potential Years of Life Lost</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.6 MRSA infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.7 Abortion rates</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.8 Depression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.9 COPD mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-discipline weighted score</td>
<td>225</td>
<td>188</td>
<td>263</td>
<td>288</td>
<td>298</td>
<td>288</td>
<td>288</td>
<td>288</td>
<td>288</td>
<td>263</td>
<td>288</td>
<td>250</td>
<td>288</td>
<td>275</td>
<td>275</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>4. Range and reach of services provided</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.1 Equity of healthcare systems</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.2 Cataract operations per 100 000 age 95+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.3 Kidney transplants per million pop.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.4 Is dental care included in the public healthcare offering?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.5 In-hospital payments to doctors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.6 Long term care for the elderly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.7 % of dialysis done outside of clinic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.8 Caesarean sections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-discipline weighted score</td>
<td>78</td>
<td>73</td>
<td>68</td>
<td>104</td>
<td>94</td>
<td>57</td>
<td>125</td>
<td>115</td>
<td>63</td>
<td>78</td>
<td>52</td>
<td>57</td>
<td>89</td>
<td>89</td>
<td>94</td>
<td>125</td>
<td>94</td>
</tr>
<tr>
<td>5. Prevention</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.1 Infant 6-disease vaccination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.2 Blood pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.3 Smoking Prevention</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.4 Alcohol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.5 Physical activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.6 HPV vaccination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.7 Traffic deaths</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-discipline weighted score</td>
<td>101</td>
<td>77</td>
<td>65</td>
<td>107</td>
<td>95</td>
<td>77</td>
<td>107</td>
<td>119</td>
<td>95</td>
<td>101</td>
<td>48</td>
<td>89</td>
<td>83</td>
<td>83</td>
<td>107</td>
<td>101</td>
<td>101</td>
</tr>
<tr>
<td>6. Pharmaceutical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.1 Rx subsidy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.2 Layman-adapted pharmacopeia?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.3 Novel cancer drugs deployment rate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.4 Access to new drugs (time to subsidy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.5 Antihypertensive drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.6 Statin use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.7 Antibiotics/capita</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-discipline weighted score</td>
<td>90</td>
<td>92</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>88</td>
<td>91</td>
<td>92</td>
<td>90</td>
<td>91</td>
<td>91</td>
<td>91</td>
<td>91</td>
<td>91</td>
<td>91</td>
<td>91</td>
<td>91</td>
</tr>
<tr>
<td>Total score</td>
<td>662</td>
<td>569</td>
<td>620</td>
<td>851</td>
<td>666</td>
<td>518</td>
<td>927</td>
<td>965</td>
<td>564</td>
<td>763</td>
<td>497</td>
<td>670</td>
<td>678</td>
<td>740</td>
<td>709</td>
<td>788</td>
<td>904</td>
</tr>
<tr>
<td>Rank</td>
<td>22</td>
<td>29</td>
<td>27</td>
<td>26</td>
<td>25</td>
<td>34</td>
<td>1</td>
<td>3</td>
<td>31</td>
<td>14</td>
<td>35</td>
<td>24</td>
<td>23</td>
<td>16</td>
<td>18</td>
<td>12</td>
<td>2</td>
</tr>
</tbody>
</table>
Indicators shaded light green in the figures above have been updated since the 2015 edition – conversely, those still white or light yellow are scored on the same data as in 2015.

Please note (Section 7.6) that the weights of the six sub-disciplines have been adjusted slightly since 2015, which is why countries can have a different score sum 2016 in spite of having the same R/Y/G scores as in 2015.

The Indicator 3.x for COPD mortality has not been included in the overall score calculation (see Section 7.10.3 for explanation).

3.1 Results Summary

![EHCI 2016 total scores chart]

Figure 3.1 EHCI 2016 total scores.

This 10th attempt at creating a comparative index for national healthcare systems has confirmed that there is a group of EU member states, which all have good healthcare systems seen from the customer/consumer’s point of view.

The scoring has intentionally been done in such a way that the likelihood that two states should end up sharing a position in the ranking is almost zero. It must therefore be noted that great efforts should not be spent on in-depth analysis of why one country is in 13th place, and another in 16th. Very subtle changes in single scores can modify the internal order of countries, particularly in the middle of the ranking list, and in the EHCI 2016 also for positions 3 - 8.

The EHCI 2016 total ranking of healthcare systems shows The Netherlands again pulling ahead, scoring 927 points out of 1000, an EHCI all-time high. Thus, the NL top position survives the onslaught of Switzerland, 904 points.

The changes in rank should not at all be dismissed as an effect of changing indicators, of which there are 48 in the EHCI 2016 – the same indicators as in the previous year. The Netherlands is the only country which has consistently been among the top three in
the total ranking of any European Index the Health Consumer Powerhouse has published since 2005. The Netherlands is sub-discipline winner, or joint winner, in four of the six sub-disciplines of the EHCI 2016. The Dutch healthcare system does not seem to have any really weak spots in the other sub-disciplines. Normally, the HCP takes care to state that the EHCI is limited to measuring the “consumer friendliness” of healthcare systems, i.e. does not claim to measure which European state has the best healthcare system across the board.

However, the fact that it seems very difficult to build an Index of the HCP type without ending up with The Netherlands on the medallists’ podium, creates a strong temptation to actually claim that the winner of the EHCI 2016 could indeed be said to have “the best healthcare system in Europe”. There should be a lot to learn from looking deeply into the Dutch progress!

Switzerland has for a long time had a reputation for having an excellent healthcare system, and it therefore comes as no surprise that the more profound research which eliminated most n.a. scores results in a prominent position in the EHCI.

Bronze medallists are Norway at 865 points. Positions 3 – 8; Norway, Belgium, Iceland, Luxembourg, Germany and Finland are all separated by only a few points.

A slight disappointment is Denmark, which for a number of years held position #2 in the EHCI; now down to 9th place in 2016. Apart from losing a few points by no longer providing hospital treatment results to the public, Denmark has lost 30 points on Accessibility since 2012. This coincides in time with Denmark introducing what might be the most rigid system in Europe for accessing healthcare services. For Danish patients, there are supposed to be only two telephone numbers to get in contact; the phone number of one’s primary care doctor, and 112!

The Swedish score for technically excellent healthcare services is, as ever, dragged down by the seemingly never-ending story of access/waiting time problems, in spite of national efforts such as Vårdgaranti (National Guaranteed Access to Healthcare). In 2016, Sweden is back into 12th place with the same 786 points, which were good for 10th place in 2015.

In southern Europe, Spain and Italy provide healthcare services where medical excellence can be found in many places. Real excellence in southern European healthcare seems to be a bit too much dependent on the consumers’ ability to afford private healthcare as a supplement to public healthcare. Also, both Spain and Italy show large regional variation, which tends to result in a lot of Amber scores for the countries.

Some eastern European EU member systems are doing surprisingly well, particularly the Czech Republic and Estonia, considering their much smaller healthcare spend in Purchasing Power adjusted dollars per capita. However, readjusting from politically planned to consumer-driven economies does take time.

Consumer and patient rights are improving. In a growing number of European countries there is healthcare legislation explicitly based on patient rights, and a functional access to your own medical record is becoming standard. Hospital/clinic catalogues with quality ranking used to be confined to two – three countries for years; the 2016 number of nine countries hopefully is a sign that something is happening in this area. Medical travel supported by the new patient mobility directive can accelerate the demand for performance transparency. After the cross-border directive, the criteria for this indicator have been tightened to reflect the implementation of this directive. Not unexpectedly, in 2013 the only countries to score Green were The Netherlands and Luxembourg, who have been allowing cross-border care seeking for years.
Generally European healthcare continues to improve but medical outcomes statistics is still appallingly poor in many countries. This is not least the case regarding the number one killer condition: cardiovascular diseases, where data for one very vital parameter; 30-day case fatality for hospitalized heart infarct patients, would have to be compiled from several disparate sources. This indicator (3.1) has therefore been modified.

If healthcare officials and politicians took to looking across borders, and to "stealing" improvement ideas from their European colleagues, there would be a good chance for a national system to come much closer to the theoretical top score of 1000. As a prominent example; if Sweden could achieve a Belgian waiting list situation, that alone would suffice to lift Sweden to compete with The Netherlands at ~880 points!

A further discussion on results of states and the changes observed over time can be found in Chapter 5: Trends over the ten years.

3.1.1 Country scores

With the possible exception of the Netherlands and Switzerland, there are no countries, which excel across the entire range of EHCI indicators. The national scores seem to reflect more of “national and organisational cultures and attitudes”, rather than mirroring how large resources a country is spending on healthcare. The cultural streaks have in all likelihood deep historical roots. Turning a large corporation around takes a couple of years – turning a country around can take decades!
3.1.2 Results in “Hexathlon”

The EHCI 2016 is made up of six sub-disciplines. As no country excels across all aspects of measuring a healthcare system, it can therefore be of interest to study how the 35 countries rank in each of the five parts of the “pentathlon”. The scores within each sub-discipline are summarized in the following table:

<table>
<thead>
<tr>
<th>Sub-discipline</th>
<th>Top country/countries</th>
<th>Score</th>
<th>Maximum score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Patient rights and information</td>
<td>Norway</td>
<td>125!</td>
<td>125</td>
</tr>
<tr>
<td>2. Accessibility</td>
<td>Belgium, FYR Macedonia, Switzerland</td>
<td>225!</td>
<td>225</td>
</tr>
<tr>
<td>3. Outcomes</td>
<td>Finland, Iceland, Germany, Netherlands, Norway, Switzerland</td>
<td>288</td>
<td>300</td>
</tr>
<tr>
<td>4. Range and reach of services</td>
<td>Netherlands, Sweden</td>
<td>125!</td>
<td>125</td>
</tr>
<tr>
<td>5. Prevention</td>
<td>Norway</td>
<td>119</td>
<td>125</td>
</tr>
<tr>
<td>6. Pharmaceuticals</td>
<td>France, Germany, Ireland, Netherlands, Switzerland</td>
<td>86</td>
<td>100</td>
</tr>
</tbody>
</table>

As the table indicates, the total top position of the Dutch healthcare system is to a great extent a product of an even performance across the sub-disciplines, very good medical quality and improved Accessibility, which used to be a weaker point in previous years.

Runner-up Switzerland is in top position for Accessibility, with Belgium. No country scores All Green on Outcomes. The Swedish healthcare system would be a real top contender, scoring high on Range & Reach of Services along with the NL, were it not for an accessibility situation, which by Belgian or Swiss standards can only be described as abysmal.
4. Bang-For-the-Buck adjusted scores

With all 28 EU member states and eight other European countries included in the EHCI project, it becomes apparent that the Index tries to compare states with very different financial resources. The annual healthcare spending, in PPP-adjusted (Purchasing Power Parity) US dollars, varies from less than $600 in Albania to above $6000 in Norway, Switzerland, and Luxembourg. Continental Western Europe and Nordic countries generally fall between $3000 and $5000. As a separate exercise, the EHCI 2016 has added a value for money-adjusted score: the Bang-For-the-Buck adjusted score, or “BFB Score”.

4.1 BFB adjustment methodology

It is not obvious how to do such an adjustment. If scores would be adjusted in full proportion to healthcare spend per capita, the effect would simply be to elevate all less affluent states to the top of the scoring sheet. This, however, would be decidedly unfair to the financially stronger states. Even if healthcare spending is PPP (Purchasing Power Parity) adjusted, it is obvious that also PPP dollars go a lot further to purchase healthcare services in member states, where the monthly salary of a nurse is €200, than in states where nurse’s salaries exceed €3500. For this reason, the PPP adjusted scores have been calculated as follows:

Healthcare spends per capita in PPP dollars have been taken from the WHO HfA database (July 2016; latest available numbers, almost all 2013) as illustrated in the graph below:

For each country has been calculated the square root of this number. The reason for this is that domestically produced healthcare services are cheaper roughly in proportion
to the healthcare spend. The basic EHCI scores have been divided by this square root. For this exercise, the basic scoring points of 3, 2 and 1 have been replaced by 2, 1 and 0. In the basic EHCI, the minimum score is 333 and the maximum 1000. With 2, 1 and 0, this does not (or only very marginally) change the relative positions of the 35 countries, but is necessary for a value-for-money adjustment – otherwise, the 333 “free” bottom points have the effect of just catapulting the less affluent countries to the top of the list.

The score thus obtained has been multiplied by the arithmetic means of all 35 square roots (creating the effect that scores are normalized back to a similar numerical value range to the original scores).

4.2 Results in the BFB Score sheet

The outcome of the BFB exercise is shown in the graphic below. Even with the square root exercise described in the previous section, the effect is to dramatically elevate many less affluent nations in the scoring sheet.

The BFB scores, naturally, are to be regarded as somewhat of an academic exercise. Not least the method of adjusting to the square root of healthcare spent certainly lacks scientific support.

With the great score increase on reduced Waiting Times, FYR Macedonia is still absolutely unstoppable in this exercise in 2016! Estonia has always been doing well in this analysis, and is now joined by the Czech Republic, Serbia and Croatia; Iceland has been well positioned since it was first included. It does seem that the supreme winner in the 2007 and 2008 BFB scores, Estonia, keeps doing well within its financial capacity. It might be that the “steel bath” forced upon Estonia after the financial crisis helped cement the cost-effective streaks of Estonian healthcare.
The Netherlands is holding out surprisingly well in this exercise. Sweden is dropping 8 positions from the effect of trying to solve waiting time problems be throwing money at them – Sweden is now a top spender along with The Netherlands and Austria, and still scores the same points as in 2015!

Again, Greece and Hungary are found together at the lower end of the ranking.

Czech Republic and Croatia were doing well in the BFB Index already in 2012. The good positions of the Czech Republic and Croatia in the BFB sheet are probably not just artefacts; The Czech Republic seems to have a degree of fundamental stability and freedom from corruption in its healthcare system, which is relatively rare in CEE states. Croatia does have “islands of excellence” in its healthcare system, and might well become a popular country for “health tourism”; there are few other places where a state-of-the-art hip joint operation can be had for €3000.

5. Trends over the 10 years

EHCI 2005 was a pilot attempt with only 12 countries and 20 indicators, and is hence not included in the longitudinal analysis.

In the responses on “Single Country Score Sheets” received from national bodies (ministries of health) in 2013, there was an unprecedented number of references to formal legislation as arguments for a higher score. A typical example was on indicator 6.4 “Time lag between registration of a drug and inclusion in subsidy system”, where several countries referring to legislation saying that the legal time limit for this is 180 days as an argument for an Amber score. In the EHCI, legislation as such is not the basis for an indicator score, as real life often shows significant implementation gaps for rules and regulations.

5.1 Score changes 2006 - 2016

From the point of view of a healthcare consumer, the overall situation is improving in most countries. However, not least after the introduction of nine new indicators in the 2012 index and a further seven new indicators in 2013, there are some countries which survive those extra tests on their healthcare systems, and some which suffer in the 2014 – 2016 scores.

Among the “survivors” are the Netherlands, Switzerland, Norway, Iceland, Denmark, Belgium, and Finland. As the “country trends” graph below is showing, the “financial crisis shock-induced(?) grumpiness” displayed in the survey responses from a number of patient organisations in 2012 seemed to have been relieved to a great extent BY 2016.

A feature, which was more prominent in post-crisis 2014 than in previous years is a stratification between affluent and less affluent countries. This gap is definitely less noticeable in 2016.

However, the performance of countries such as Portugal, FYR Macedonia and, in 2016, Serbia shows that GDP/capita need not be a dominating factor. Among the very few, where the 10-year trend over time is flat (i.e. not rising), are countries as different as Sweden and Romania, plus Greece which seems to be recovering from a dive in 2012.
Figure 5.1. The results over the nine years 2006 – 2016.
5.1.1 Ranking strictly relative – a lower position does not necessarily mean deterioration of services

The fact that most countries show an upward trend in this normalized calculation can be taken as an indication that European healthcare is indeed improving over time. That some countries have a downward trend among other countries cannot be interpreted in the way that their healthcare systems have become worse over the time studied – only that they have developed less positively than the European average!

5.2 Healthcare Quality Measured as Outcomes

For a detailed view of the results indicators, please see section 7.10.3 in order to study development over time. Generally it is important to note that regardless of financial crises and austerity measures, treatment results in European healthcare keep improving. Perhaps the best single indicator on healthcare quality, 3.3 Infant deaths, where the cut-offs between Red/Amber/Green scores have been kept constant since 2006, shows an increase in the number of Green scores from 9 in 2006 to 24 in 2016. The figure below shows the “healthcare quality map” of Europe based on the Outcomes sub-discipline scores in EHCI 2016:

Outcomes scores in EHCI 2016
This map is fairly constant over time, but the Green area is slowly but securely expanding. Some CEE countries which were definitely Red in 2006 have climbed into Amber scores, and Germany, which used to score Amber is today safely in the Green territory. Portugal, Slovenia and the U.K. also pull into the Green area for the first time in 2016. Ireland and Belgium have also got their quality acts together. Austria (and Sweden) are handicapped by the Indicator Abortion rate being considered as an Outcome.

That Italy and the Spain (“Big Beveridge”) are still Amber is probably due to large regional variation; both countries most certainly have many centres of excellence in healthcare, but the national scores tend to be a rather bleaker Yellow.

5.2.1 The LAP indicator – money can buy better outcomes!

Even though the “Big Beveridge” states do less well than their Bismarck colleagues, there seems to be a definite correlation between money spent and medical treatment results, as is shown by the Graph below: (R)

![Graph showing correlation between Outcomes and money spent](image)

**Figure 5.2.1.** The correlation between Outcomes and money spent is quite strong (“R” down slightly from 85.4% in 2015 to 82.7%! Finland and Iceland do well in relation to money spent!

There probably are several reasons why money can buy better outcomes, apart from the obvious of affording top experts and state-of-the-art technical facilities. Another reason seems to be that more generous funding allows for admitting patients on weaker indications. This can be shown by the “Level of Attention to the Problem” (LAP) indicator, one illustration of which is found in the Graph below. The graph shows the relation between “the ratio of hospital discharges over deaths for heart disease” and the *per capita* healthcare spend. If the ratio of hospital discharges over deaths is high, it would indicate that patients are admitted on weaker indications.
The correlation is noticeable. Also noticeable is the interesting fact that crisis-stricken Greeks cannot only afford lots of drugs (see Section 1.3.28), but can somehow afford to be very generous on cardiac care hospital admissions in relation to their official healthcare spend numbers!

![Graph showing the correlation between ratio of discharges/deaths and HC spend/capita (PPP$) for Greece.](image)

Figure 5.2.2. An example of the LAP indicator from EHCI 2014.

### 5.3 Transparent monitoring of healthcare quality

In 2005, Dr. Foster of the UK was the single shining star on the firmament of provider (hospital) listing, where patients could actually see which hospitals had good results in term of actual success rates or survival percentages.

In 2007, there were already a couple more examples, where the Health Consumer Powerhouse believes that the most notable is the Danish [www.sundhedskvalitet.dk](http://www.sundhedskvalitet.dk), where hospitals are graded from ★ to ★★★★★ as if they were hotels, with service level indicators as well as actual results, including case fatality rates on certain diagnoses. Perhaps the most impressive part of this system was that it allows members of the public to click down to a link giving the direct-dial telephone number of clinic managers. Regrettably, the Danish system no longer contains actual treatment results, only how frequently hospitals perform certain procedures.

Germany did join the limited ranks of countries (today seven) scoring Green by the power of the public institute BQS, [www.bqs-institut.de](http://www.bqs-institut.de), which also provides results quality information on a great number of German hospitals. Possibly, this could be a small part of the reason why German healthcare quality in 2016 is safely in the “Green territory” (see above).

Estonia, The Netherlands, Norway, Portugal and Slovakia have joined the ranks of countries providing this information to the public. So does Sweden, albeit in a
publication ("Öppna jämförelser"), which is not really aimed at the general public. We can also find not-so-perfect, but already existing, catalogues with quality ranking in Cyprus, Hungary, FYR Macedonia, Italy (regional; Tuscany et al.) and Slovenia! In France, the HCP team still have not found any other open benchmark than the weeklies *Le Point* and *Figaro Magazine* annual publishing of “The best clinics of France”. As French patient organisations were top of Europe at knowing about this service, France gets a Green score on the strength of this.

Ministry sources of FYR Macedonia claim that they will shortly begin publishing lists of “the 100 best doctors”. That will be most interesting to follow, not least from a methodology standpoint! Publishing results at individual physician level is also starting in the UK.

5.4 Layman-adapted comprehensive information about pharmaceuticals

In a discussion as late as January 2007, a representative of the Swedish Association of Pharmaceutical Industry (LIF), who were certainly pioneers with their well-established pharmacopoeia “Patient-FASS” (www.fass.se), was arguing that this and its Danish equivalent were the only examples of open information about prescription drugs in Europe. Today, easy-to-use web-based instruments to access information on pharmaceuticals can be found in 30 countries (see Section 7.10.6, indicator 6.2). Citizens of the few remaining countries can normally access this information from a neighbouring country in a language they can understand. The vast majority of these information sites have information providers clearly identifiable as the pharmaceutical manufacturers. As was predicted in the EHCI 2015 report, this indicator has essentially ceased to be of comparative interest and probably not be included in EHCI 2017.

5.5 Waiting lists: A Mental Condition affecting healthcare staff?

Over the years, one fact becomes clear: gatekeeping means waiting. Contrary to popular belief, direct access to specialist care does not generate access problems to specialists by the increased demand; repeatedly, waiting times for specialist care are found predominately in systems requiring referral from primary care, which seems to be rather an absurd observation.
Figure 5.5a. “Waiting time territory” (red) and Non-wait territory (green) based on EHCI 2016 scores (mainly the same data for both years).

The “waiting time territory” situation is remarkably stable over time. There is virtually no correlation between money and Accessibility of healthcare system, as is shown by the Graph below. This could explain the limited effect of showering a billion euros over Swedish counties to make them reduce waiting times.
Figure 5.5b. R = +26 % (down 4 % since 2015). Any correlation coefficient (R) lower than 50 % means essentially no correlation.

It seems that waiting times for healthcare services are a mental condition affecting healthcare administrators and professionals rather than a scarcity of resources problem. It must be an interesting behavioural problem to understand how an empathic profession such as paediatric psychiatrists can become accustomed to telling patients and their parents that the waiting time for an appointment is in the order of 18 months for a child with psychiatric problems (a common occurrence in Sweden)!

The Swedish queue-shortening project, on which the state government has spent approximately one billion euro, has achieved some shortening of waiting times. Sadly, that improvement, which unfortunately does not seem to have succeeded on waiting times for cancer treatment, still in 2016 has been insufficient to make Sweden leave the group of laggard countries.

One of the most characteristic systems for GP gatekeeping, the NHS in the UK, spent millions of pounds, starting in 2008, on reducing waiting and introduced a maximum of 18 weeks to definitive treatment after diagnosis. The patient survey commissioned by the HCP for the 2012 and 2013 Indices did show improvement, some of which seems to have been lost in 2016.

This is different from Ireland, where patient organisation survey responses are still much more negative than (the very detailed) official waiting time data. For this reason, after several years of accepting official Irish waiting time statistics, the EHCI 2016 has scored Ireland on patients’ versions of waiting times.

Furthermore, even the strong winners of past years’ rankings have been turning to restrictive measures: France, for example, was restraining access in 2007, which resulted in waiting times, and therefore worse score (together with not really brilliant results in the e-Health sub-discipline). Since 2009, French patients (and doctors?) seem
to have learned to work the new regulations, as the French survey responses on this sub-discipline are today more positive. Also, about French waiting times in healthcare, see Appendix 1!

HCP will continue to advocate the free choice, equal and direct access and measures intended to diminish the information handicap of the consumer as cornerstones of 21st century modern European healthcare.

5.5.1 Why is there no correlation between accessibility and money?

Answer: Because it is inherently cheaper to run a healthcare system without waiting lists than having waiting lists! Contrary to popular belief, not least among healthcare politicians, waiting lists do not save money – they cost money!

Healthcare is basically a process industry. As any professional manager from such an industry would know, smooth procedures with a minimum of pause or interruption is key to keeping costs low!

5.5.2 The “good old days” that never were!

Why are the traces of the “financial crisis” so comparatively modest, particularly regarding medical treatment results (Outcomes)? One fundamental reason is that healthcare traditionally used to be very poor at monitoring output, which leads healthcare staff, politicians and the public to overestimate the service levels of yesteryear!

Cost-cutting in healthcare was not talked about much until the early 1990’s, and the economic downturn at that time, which forced serious cost-cutting more or less for the first time in decades. Before 1990, healthcare politicians’ main concern used to be “How do we prioritize the 2 – 3% annual real-term increase of resources?”

In waiting time territory such as Scandinavia and the British Isles, the waiting list situation was decidedly worse not only 5 – 10 years ago, but most certainly also before 1990. Interviews with old-timer doctors and nurses frequently reveal horror stories of patients all over corridors and basements, and this from the “good old days” before the financial crisis.

5.5.3 Under-the-table payments

Even more notable: one of the indicators, introduced for the first time in 2008, is asking whether patients are expected to make informal payments to the doctor in addition to any official fees. Under-the-table payments serve in some (rather surprising Western European) countries as a way to gain control over the treatment: to skip the waiting list, to access excellence in treatment, to get benefit of modern methods and medicines. More on informal payments can be found in the section Informal payments to doctors.

The cross-European survey on informal payments remains, in spite of its obvious imperfections, the only study ever done on all of Europe, which also illustrates the low level of attention paid by nations and European institutions to the problem of parallel economy in healthcare.

This observation gives reason for two questions:

1. Unlike other professionals, such as airline pilots, lawyers, systems engineers etc, working for large organisations, doctors are unique in being allowed to run side
jobs without the explicit permission of the main employer. What is the reason(s) for keeping that?

2. What could be done to give doctors “normal” professional employment conditions, i.e. a decent salary and any extra energy spent on working harder (yes, and making more money) for their main employer, instead of disappearing to their side practices, frequently leaving large hospitals standing idle for lack of key personnel?

5.6 Why do patients not know?

Each year, the results of the survey made in co-operation with Patient View reveal an interesting fact: in some countries, the patients’ organisations and health campaigners (even very respectful ones) do not know about some of the services available in their country. Interestingly, this has probably as evident in 2016 as in previous years. The Single Country Score Sheets returned from national bodies have had as a very common feature that officials have, with a more or less irritated vocabulary, pointed out that certain patient rights or information services indeed do exist in their country.

For example, the research team constantly finds negative answers on the existence of doctors’ registries, pharmacopoeias, access to medical records etc. in countries where HCP researchers can easily find this kind of information even without the knowledge of local language. To sum up, probably the reason is that national authorities make considerable improvements, but miss out on communicating these to the wide public. As healthcare moves from a top-down expert culture into a communication-driven experience industry, such a situation must be most harmful to users as well as taxpayers and systems!

Three countries, where the opinions of patient organisations are deviating negatively from official statistics, are Greece, Ireland and Spain. One example: Spanish regulations do give patients the right to read their own patient records – nevertheless, Spanish patient organisations returned among the most pessimistic responses to this survey question of any of the 35 countries!

In private industry, it is well known and established knowledge that a product or service, be it ever so well designed and produced, needs skilful marketing to reach many customers. In the public sector in general, the focus is (at best) on planning and production of a service, but there is frequently an almost total lack of focus on the information/marketing of that service.

**European healthcare needs to increase its focus on informing citizens about what services are available!**

5.7 MRSA spread

In the EHCI 2007, considerable attention was paid to the problem of antibiotics resistance spread: “MRSA infections in hospitals seem to spread and are now a significant health threat in one out of two measured countries.” Unfortunately, the only countries where significant improvement can be seen are Bulgaria, Poland and the British Isles. Only seven countries out of 35 today can say that MRSA is not a major problem, thus scoring Green – rather depressingly, these are the same seven countries as in 2009!
The most dramatic reduction of MRSA rates has taken place in the UK, where the % of resistant infections has dropped from ~40 % down to ~15 %. This must be a result of intense efforts in hospital hygiene, as the British Isles are still among the most pronounced over-users of antibiotics, according to pharmaceutical industry sales numbers.

5.7.1 Ban sales of antibiotics without prescription!

There is one measure, which could be very effective against the spread of microbial resistance; the banning of sales of antibiotics without a prescription. This could become an easily formulated EU directive, which also would be quite simple to monitor, as all countries do have systems to check the distinction between Rx (prescription) and OTC (Over The Counter) drug sales. There is no country, where sales of antibiotics without a prescription is commonplace, which does not have a significant resistance problem!

Such Brussels action would mean far more to patient safety than most other things EU engages in!

6. How to interpret the Index results?

The first and most important consideration on how to treat the results is: with caution!

The Euro Health Consumer Index 2016 is an attempt at measuring and ranking the performance of healthcare provision from a consumer viewpoint. The results definitely contain information quality problems. There is a shortage of pan-European, uniform set procedures for data gathering. Still, European Commission attempts to introduce common, measurable health indicators have made very little impact. As the Commission now moves ahead to develop approaches to assess the performance of national healthcare systems, there further challenges to tackle.

Again, the HCP finds it far better to present the results to the public, and to promote constructive discussion rather than staying with the only too common opinion that as long as healthcare information is not a hundred percent complete it should be kept in the closet. Again, it is important to stress that the Index displays consumer information, not medically or individually sensitive data.

While by no means claiming that the EHCI 2016 results are dissertation quality, the findings should not be dismissed as random findings. The Index is built from the bottom up – this means that countries who are known to have quite similar healthcare systems should be expected not to end up far apart in the ranking. This is confirmed by finding the Nordic countries in a fairly tight cluster, England and Scotland clinging together as are the Czech Republic and Slovakia, Spain and Portugal, Greece and Cyprus.

Previous experience from the general Euro Health Consumer Indexes reflects that consumer ranking by similar indicators is looked upon as an important tool to display healthcare service quality. The HCP hopes that the EHCI 2016 results can serve as inspiration for how and where European healthcare can be improved.
7. Evolvement of the Euro Health Consumer Index

7.1 Scope and content of EHCI 2005

Countries included in the EHCI 2005 were: Belgium, Estonia, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, Sweden, the United Kingdom and, for comparison, Switzerland.

To include all 25 member states right from the start would have been a very difficult task, particularly as many memberships were recent, and would present dramatic methodological and statistic difficulties.

The EHCI 2005 was seeking a representative sample of large and small, long-standing and recent EU membership states.

The selection was influenced by a desire to include all member states with a population of ~40 million and above, along with the above-mentioned mix of size and longevity of EU membership standing. As the Nordic countries have fairly similar healthcare systems, Sweden was selected to represent the Nordic family, purely because the project team members had a profound knowledge of the Swedish healthcare system.

As already indicated, the selection criteria had nothing to do with healthcare being publicly or privately financed and/or provided. For example, the element of private providers is specifically not at all looked into (other than potentially affecting access in time or care outcomes).

One important conclusion from the work on EHCI 2005 was that it is indeed possible to construct and obtain data for an index comparing and ranking national healthcare systems seen from the consumer/patient’s viewpoint.

7.2 Scope and content of EHCI 2006 – 2014

The EHCI 2006 included all the 25 EU member states of that time plus Switzerland, using essentially the same methodology as in 2005.

The number of indicators was also increased, from 20 in the EHCI 2005 to 28 in the 2006 issue. The number of sub-disciplines was kept at five; with the change that the “Customer Friendliness” sub-discipline was merged into “Patient Rights and Information”. The new sub-discipline “Generosity” (What is included in the public healthcare offering?) was introduced, as it was commented from a number of observers, not least healthcare politicians in countries having pronounced waiting time problems, that absence of waiting times could be a result of “meanness” – national healthcare systems being restrictive on who gets certain operations could naturally be expected to have less waiting list problems.

In order to test this, the new sub-discipline “Generosity” of public healthcare systems, in 2009 called “Range and reach of services”, was introduced. A problem with this sub-discipline is that it is only too easy to land in a situation, where an indicator becomes just another way of measuring national wealth (GDP/capita). The suggested indicator “Number of hip joint replacements per 100 000 inhabitants” is one prominent example of this. The cost per operation of a hip joint is in the neighbourhood of € 7000 (can be more in Western Europe – less in states with low salaries for healthcare staff). That
cost, for a condition that might be crippling but not life-threatening, results in provision levels being very closely correlated to GDP/capita.

Cataract operations seem a better and less GDP-correlated indicator on the Generosity of public healthcare systems. The cost per operation is only one tenth of that for a hip joint and thus much more affordable in less affluent countries.

To achieve a higher level of reliability of information, one essential work ingredient has been to establish a net of contacts directly with national healthcare authorities in a more systematic way than was the case for previous EHCI editions. The weaknesses in European healthcare statistics described in previous EHCI reports can only be offset by in-depth discussions with key personnel at a national healthcare authority level.

In general, the responsiveness from Health Ministries, or their state agencies in charge of supervision and/or Quality Assurance of healthcare services, was good in 2006 – 2008. Written responses were received from 19 EU member states. This situation greatly improved in 2009 – 2012 and stayed very positive in 2016 (see section 8.9.2).

7.3 EHCI 2016

The project work on the Index is a compromise between which indicators were judged to be most significant for providing information about the different national healthcare systems from a user/consumer’s viewpoint, and the availability of data for these indicators. This is a version of the classical problem “Should we be looking for the 100-dollar bill in the dark alley, or for the dime under the lamppost?”

It has been deemed important to have a mix of indicators in different fields; areas of service attitude and customer orientation as well as indicators of a “hard facts” nature showing healthcare quality in outcome terms. It was also decided to search for indicators on actual results in the form of outcomes rather than indicators depicting procedures, such as “needle time” (time between patient arrival to an A&E department and trombolytic injection), percentage of heart patients trombolysed or stented, etcetera.

Intentionally de-selected were indicators measuring public health status, such as life expectancy, lung cancer mortality, total heart disease mortality, diabetes incidence, etc. Such indicators tend to be primarily dependent on lifestyle or environmental factors rather than healthcare system performance. They generally offer very little information to the consumer wanting to choose among therapies or care providers, waiting in line for planned surgery, or worrying about the risk of having a post-treatment complication or the consumer who is dissatisfied with the restricted information.

7.3.1 New indicators introduced for EHCI 2016

The indicator set is the same in the EHCI 2016 as it was in 2014 and 2015, with one exception.

Sub-discipline 6 (Pharmaceuticals):

This sub-discipline is the same as in previous editions, except:

- Indicator 6.6 measures deployment rates of statins instead of metformin.


**7.4 Indicator areas (sub-disciplines)**

The 2013 Index is, just like previous EHCI editions, built up with indicators grouped in six (this number has varied) sub-disciplines.

The EHCI 2013 was given a sixth sub-discipline, Prevention, as many interested parties (both ministries and experts) have been asking for that aspect to be covered in the EHCI. One small problem with Prevention might be that many preventive measures are not necessarily the task of healthcare services. The Index at least tries to concentrate on such aspects of Prevention, which can be affected by human decision makers in a reasonably short time frame.

After having had to surrender to the "lack of statistics syndrome", and after scrutiny by the expert panel, 48 indicators survived into the EHCI 2016.

The indicator areas for the EHCI 2016 are:

<table>
<thead>
<tr>
<th>Sub-discipline</th>
<th>Number of indicators</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Patient rights and information</td>
<td>12</td>
</tr>
<tr>
<td>2. Accessibility/Waiting time for treatment</td>
<td>6</td>
</tr>
<tr>
<td>3. Outcomes</td>
<td>8</td>
</tr>
<tr>
<td>4. Range and reach of services (&quot;Generosity&quot;)</td>
<td>8</td>
</tr>
<tr>
<td>5. Prevention</td>
<td>7</td>
</tr>
<tr>
<td>6. Pharmaceuticals</td>
<td>7</td>
</tr>
</tbody>
</table>

**7.5 Scoring in the EHCI 2016**

The performance of the respective national healthcare systems were graded on a three-grade scale for each indicator, where the grades have the rather obvious meaning of Green = good (☝️), Amber = so-so (🍁) and red = not-so-good (☒). A green score earns 3 points, an amber score 2 points and a red score (or a “not available”, n.a.) earns 1 point.

Having six non-EU countries in the Index, who should not be stigmatized for not (yet) being EU member states on indicator “1.8 Free choice of care in another EU state”, forced the introduction of a new score in the EHCI 2009: “not applicable”. These countries therefore receive the “n.ap.” score, which earns 2 points. That score was also applied on indicator 1.9 for Iceland and Malta, as they essentially have only one real hospital each.

In 2013, a Purple score: ☕️, earning 0 points, was introduced for particularly abominable results. It has been exclusively applied on indicator “3.7 Abortion rates” for countries not giving women the right to abortion.

Since the 2006 Index, the same methodology has been used: For each of the sub-disciplines, the country score is calculated as a percentage of the maximum possible (e.g. for Waiting times, the score for a state has been calculated as % of the maximum 3 x 6 = 18).
Thereafter, the sub-discipline scores were multiplied by the weight coefficients given in the following section and added up to make the final country score. These percentages were then rounded to a three digit integer, so that an “All Green” score on the 48 indicators would yield 1000 points. “All Red” gives 333 points.

### 7.6 Weight coefficients

The possibility of introducing weight coefficients was discussed already for the EHCI 2005, i.e. selecting certain indicator areas as being more important than others and multiplying their scores by numbers other than 1.

For the EHCI 2006, explicit weight coefficients for the five sub-disciplines were introduced after a careful consideration of which indicators should be considered for higher weight. The accessibility and outcomes sub disciplines were decided as the main candidates for higher weight coefficients based mainly on discussions with expert panels and experience from a number of patient survey studies.

In the EHCI 2016, the scores for the five sub-disciplines were given the following weights. The HCP has always strived to have a high weight on treatment Outcomes, as those are frequently judged by patient surveys as being the most essential for a healthcare system. In the early years of Index production, HCP received much criticism for this, based on the illusion that “the best doctors and hospitals get the most difficult cases, and therefore worse Outcomes”. That notion is totally unsupported by hospital comparisons.

Much to the delight of the HCP, during 2016 some of the very same critics, who used to claim that Outcomes indicators were unfair, criticised the EHCI for not giving a high enough weight to Outcomes. Trying to be responsive as always, the Outcomes weight was raised from 250 in 2015, to 300 in the 2016 edition. This was compensated for, within the total of 1000, by lowering the weights of sub-disciplines 1. and 4. by 25 points each.

<table>
<thead>
<tr>
<th>Sub-discipline</th>
<th>Relative weight (&quot;All Green” score contribution to total maximum score of 1000)</th>
<th>Points for a Green score in each sub-discipline</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Patient rights, information and e-Health</td>
<td>125</td>
<td>10.42</td>
</tr>
<tr>
<td>2. Accessibility (Waiting time for treatment)</td>
<td>225</td>
<td>37.50</td>
</tr>
<tr>
<td>3. Outcomes</td>
<td>300</td>
<td>37.50</td>
</tr>
<tr>
<td>4. Range and reach of services (&quot;Generosity&quot;)</td>
<td>125</td>
<td>15.62</td>
</tr>
<tr>
<td>5. Prevention</td>
<td>125</td>
<td>17.85</td>
</tr>
<tr>
<td>6. Pharmaceuticals</td>
<td>100</td>
<td>14.29</td>
</tr>
<tr>
<td><strong>Total sum of weights</strong></td>
<td><strong>1000</strong></td>
<td></td>
</tr>
</tbody>
</table>
Consequently, as the percentages of full scores were added and multiplied by 
(1000/Total sum of weights), the maximum theoretical score attainable for a national 
healthcare system in the Index is 1000, and the lowest possible score is 333.

It should be noted that, as there are not many examples of countries that excel in one 
sub-discipline but do very poorly in others, the final ranking of countries presented by 
the EHCI 2016 is remarkably stable if the weight coefficients are varied within rather 
wide limits.

The project has been experimenting with other sets of scores for green, amber and red, 
such as 2, 1 and 0 (which would really punish low performers), and also 4, 2 and 1, 
(which would reward real excellence). The final ranking is remarkably stable also during 
these experiments.
## 7.7 Indicator definitions and data sources for the EHCI 2016

It is important to note, that since 2009, the HCP has been receiving much more active feedback from national healthcare agencies in all but a few of the 35 countries. In those cases, the responses in the survey commissioned from Patient View 2016 have been applied very cautiously, e.g. when the “official” data says Green, and the survey says “definitely Red”, the country has been awarded a Yellow score.

<table>
<thead>
<tr>
<th>Sub-discipline</th>
<th>Indicator</th>
<th>Comment</th>
<th>Score 3</th>
<th>Score 2</th>
<th>Score 1</th>
<th>Main Information Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.2 Patient organisations involved in decision making</td>
<td>Yes, statutory</td>
<td>Yes, by common practice in advisory capacity</td>
<td>No, not compulsory or generally done in practice</td>
<td>Patients' Perspectives of Healthcare Systems in Europe; survey commissioned by HCP 2015. Personal interviews.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.3 No-fault malpractice insurance</td>
<td>Can patients get compensation without the assistance of the judicial system in proving who made a mistake?</td>
<td>Yes</td>
<td>Fair; &gt; 25% invalidity covered by the state</td>
<td>No</td>
<td>Swedish National Patient Insurance Co. (All Nordic countries have no1fault insurance); <a href="http://www.hse.ie">www.hse.ie</a>; <a href="http://www.hiqa.ie">www.hiqa.ie</a>.</td>
</tr>
<tr>
<td></td>
<td>1.4 Right to second opinion</td>
<td>Yes</td>
<td>Yes, but difficult to access due to bad information, bureaucracy or doctor negativism</td>
<td>No</td>
<td>Patients' Perspectives of Healthcare Systems in Europe; survey commissioned by HCP 2015. Personal interviews.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.5 Access to own medical record</td>
<td>Can patients read their own medical records?</td>
<td>Yes, they get a copy by simply asking their doctor(s)</td>
<td>No such statutory right.</td>
<td>Patients' Perspectives of Healthcare Systems in Europe; survey commissioned by HCP 2015. Personal interviews; <a href="http://www.dohc.ie">www.dohc.ie</a>.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.6 Registry of bona fide</td>
<td>Can the public readily access the info: “Is doctor X a bona fide”</td>
<td>Yes, on the www or in widely spread publication</td>
<td>No</td>
<td>Survey commissioned from Patient View by HCP 2015. National physician registries; <a href="http://www.sst.dk/Tilsyn/Individuelt_tilsyn/Tilsyn_med_faglighed/Skaerpet_tilsyn_med_professional%20%22walk-through%22.pdf">www.sst.dk/Tilsyn/Individuelt_tilsyn/Tilsyn_med_faglighed/Skaerpet_tilsyn_med_professional%20&quot;walk-through&quot;.pdf</a></td>
<td></td>
</tr>
<tr>
<td>Sub-discipline</td>
<td>Indicator</td>
<td>Comment</td>
<td>Score 3</td>
<td>Score 2</td>
<td>Score 1</td>
<td>Main Information Sources</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>1.7 Web or 24/7 telephone HC info with interactivity</td>
<td>Information which can help a patient take decision such as wait or seek care immediately.</td>
<td>Yes</td>
<td>Yes, but not generally available, or poorly marketed to the public</td>
<td>No or sporadic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.10 EPR penetration</td>
<td>% of GP practices using electronic patient records for diagnostic data</td>
<td>≥ 90 % of GP practices</td>
<td>&lt;90 ≥ 50 % of practices</td>
<td>&lt; 50 % of practices</td>
<td><a href="http://ec.europa.eu/public_opinion/flash/fl1126_fr.pdf">http://ec.europa.eu/public_opinion/flash/fl1126_fr.pdf</a>; <a href="http://www.europartnersearch.net/ist/communities/indexmapconso.php?Se=11">http://www.europartnersearch.net/ist/communities/indexmapconso.php?Se=11</a>; <a href="http://www.icgp.ie">www.icgp.ie</a>; Commonwealth Fund International Health Policy Survey of Primary Care Physicians&quot;Benchmarking ICT use among GP:s in Europe&quot;; European Commission, April 2008; study made by Empirica, Bonn, Germany (p.60), Gartner Group.</td>
<td></td>
</tr>
<tr>
<td>1.11 Patients’ access to on-line booking of appointments?</td>
<td>Can patients book doctor appointments on-line?</td>
<td>Yes, widely available</td>
<td>With some pioneer hospitals/clinics</td>
<td>No, or very rare</td>
<td>Survey commissioned by HCP from Patient View 2015. Interviews with healthcare officials.</td>
<td></td>
</tr>
<tr>
<td>1.12 e-prescriptions</td>
<td>Fully functional ePrescription services across the country or substantial parts of certain regions</td>
<td>Some pharmacies have this service</td>
<td>No, or very rare.</td>
<td>Survey commissioned by HCP from Patient View 2015. Interviews with healthcare officials.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Family doctor same day access</td>
<td>Can I count on seeing my primary care doctor today? Without referral from family doctor (GP)</td>
<td>Yes</td>
<td>Yes, but not quite fulfilled</td>
<td>No</td>
<td>Survey commissioned from Patient View by HCP 2015. National healthcare agencies.</td>
<td></td>
</tr>
<tr>
<td>2.2 Direct access to specialist</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Survey commissioned by HCP from Patient View 2015. Interviews with healthcare officials, feedback from national agencies.</td>
<td></td>
</tr>
<tr>
<td>2.3 Major elective surgery &lt;90 days</td>
<td>Coronary bypass/PTCA and hip/knee joint</td>
<td>90% &lt;90 days</td>
<td>50 - 90% &lt;90 days</td>
<td>&gt; 50% &gt; 90 days</td>
<td>Survey commissioned by HCP from Patient View 2015. Interviews with healthcare officials, feedback from national agencies.</td>
<td></td>
</tr>
<tr>
<td>Sub-discipline</td>
<td>Indicator</td>
<td>Comment</td>
<td>Score 3</td>
<td>Score 2</td>
<td>Score 1</td>
<td>Main Information Sources</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>2.4 Cancer therapy &lt; 21 days</td>
<td>Time to get radiation/ chemotherapy after decision</td>
<td>Typically &lt;7 days</td>
<td>Typically &lt;21 days</td>
<td>Typically &gt; 21 days</td>
<td>Survey commissioned by HCP from Patient View 2015. Interviews with healthcare officials, feedback from national agencies. <a href="http://www.socialstyrelsen.se">www.socialstyrelsen.se</a>: Väntetider cancervård</td>
<td></td>
</tr>
<tr>
<td>2.5 CT scan &lt; 7 days</td>
<td>Wait for advanced diagnostic (non-acute)</td>
<td>Typically &lt;1 hour</td>
<td>Typically 1 - 3 hours</td>
<td>Typically &gt; 3 hours</td>
<td>Survey commissioned by HCP from Patient View 2015. Interviews with healthcare officials, feedback from national agencies. <a href="http://www.socialstyrelsen.se">www.socialstyrelsen.se</a>: Väntetider cancervård</td>
<td></td>
</tr>
<tr>
<td>2.6 A&amp;E waiting times</td>
<td>&quot;Waiting time&quot;: the period between arrival at the hospital door and when a doctor starts treating/attending the problem.</td>
<td>90% &lt; 21 days</td>
<td>50 - 90% &lt;21 days</td>
<td>&gt; 50% &gt; 21 days</td>
<td>Survey commissioned by HCP from Patient View 2015. Interviews with healthcare officials, feedback from national agencies. <a href="http://www.socialstyrelsen.se">www.socialstyrelsen.se</a>: Väntetider cancervård</td>
<td></td>
</tr>
</tbody>
</table>

3. Outcomes

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Comment</th>
<th>Score 3</th>
<th>Score 2</th>
<th>Score 1</th>
<th>Main Information Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Decrease of CVD deaths</td>
<td>Inclination of ischaemic heart disease death trend line (log values)</td>
<td>Sharp decline</td>
<td>Moderate decline</td>
<td>Weak decline</td>
<td>WHO HfA database, July 2016</td>
</tr>
<tr>
<td>3.2 Decrease of stroke deaths</td>
<td>Inclination of stroke death trend line (log values)</td>
<td>Sharp decline</td>
<td>Moderate decline</td>
<td>Weak decline</td>
<td>WHO HfA database, July 2016</td>
</tr>
<tr>
<td>3.3 Infant deaths</td>
<td>per 1000 live births</td>
<td>&lt;4</td>
<td>&lt; 6</td>
<td>≥6</td>
<td>WHO Europe Health for All mortality database July 2016, latest available statistics.</td>
</tr>
<tr>
<td>3.4 Cancer survival</td>
<td>1 minus ratio of mortality/incidence 2012 (&quot;survival rate&quot;)</td>
<td>≥ 60 %</td>
<td>59.9 - 50 %</td>
<td>&lt; 50 %</td>
<td>J. Ferlay et al. / European Journal of Cancer 49 (2013) 1374–1403</td>
</tr>
<tr>
<td>3.5 Potential Years of Life Lost</td>
<td>All causes, Years lost, /100000 population, age standardised</td>
<td>&lt; 4000</td>
<td>4001 - 6000</td>
<td>&gt; 6000</td>
<td>WHO Europe Detailed Mortality Database, October 2016</td>
</tr>
<tr>
<td>3.7 Abortion rates</td>
<td># per 1000 live births; low = Good, banned= purple</td>
<td>&lt; 200</td>
<td>201 - 300</td>
<td>&gt; 300</td>
<td>WHO Health for All Database July 2016, United Nations Information on Abortion</td>
</tr>
<tr>
<td>3.8 Depression</td>
<td>Average score on 5 mental health questions</td>
<td>≥ 67 %</td>
<td>96 - 5 5 %</td>
<td>&lt; 5 5 %</td>
<td>Special Eurobarometer 345, October 2011: <a href="http://www.fhi.no">www.fhi.no</a> “Psykisk helse i Norge 2011:2”, <a href="http://worlddatabaseofhappiness.eur.nl/hap_nat/nat_fp.php?mode=8">http://worlddatabaseofhappiness.eur.nl/hap_nat/nat_fp.php?mode=8</a></td>
</tr>
<tr>
<td>3.x COPD mortality</td>
<td>Respiratory disease SDR, minus pneumonia and</td>
<td>&lt; 20</td>
<td>20 - 30</td>
<td>&gt; 30</td>
<td>WHO Europe Detailed Mortality Database, October 2016</td>
</tr>
<tr>
<td>Sub-discipline</td>
<td>Indicator</td>
<td>Comment</td>
<td>Score 1</td>
<td>Score 2</td>
<td>Score 3</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>≥ 80 %</td>
<td>&gt;80 % - 70 %</td>
<td>≤ 70 %</td>
</tr>
<tr>
<td></td>
<td>4.1 Equity of healthcare systems</td>
<td>Public HC spend as % of total HC spend</td>
<td>≥ 80 %</td>
<td>&gt;80 % - 70 %</td>
<td>≤ 70 %</td>
</tr>
<tr>
<td></td>
<td>4.2 Cataract operations per 100 000 age 65+</td>
<td>Total number of procedures divided by 100 000's of pop. ≥ 65 years</td>
<td>&gt; 5000</td>
<td>5000 - 3000</td>
<td>&lt; 3000</td>
</tr>
<tr>
<td></td>
<td>4.5 Informal payments to doctors</td>
<td>Mean response to question: &quot;Would patients be expected to make unofficial payments?&quot;</td>
<td>No!</td>
<td>Sometimes; depends on the situation</td>
<td>Yes, frequently</td>
</tr>
<tr>
<td></td>
<td>4.6 Long term care for the elderly</td>
<td># of nursing home and elderly care beds per 100 000 population 65+</td>
<td>≥ 5000</td>
<td>4999 - 3000</td>
<td>&lt; 3000</td>
</tr>
<tr>
<td></td>
<td>4.7 % of dialysis done outside of clinic</td>
<td>% of all Dialysis patients on PD or HD in the home</td>
<td>≥ 15 %</td>
<td>&lt;15 % - 8 %</td>
<td>&lt; 8 %</td>
</tr>
<tr>
<td></td>
<td>4.8 Caesarean sections</td>
<td>% of all live births; low = Good pre-natal care</td>
<td>&lt; 200</td>
<td>201 - 300</td>
<td>&gt; 300</td>
</tr>
<tr>
<td></td>
<td>5.1 Infant 8-disease vaccination</td>
<td>Tetanus, pertussis, polioyelitis, haemophilus influenza B, hepatitis B, measles, mumps, rubella arithmetic mean</td>
<td>≥95.0 %</td>
<td>≥90.0 - 94.9 %</td>
<td>≤89.9 %</td>
</tr>
<tr>
<td>Sub-discipline</td>
<td>Indicator</td>
<td>Comment</td>
<td>Score 3</td>
<td>Score 2</td>
<td>Score 1</td>
</tr>
<tr>
<td>----------------</td>
<td>----------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>5.2 Blood pressure</td>
<td>% of people 18+ with a blood pressure &gt; 140/90</td>
<td>≤ 25%</td>
<td>&gt;25 - 30 %</td>
<td>&gt; 30 %</td>
<td>WHO Global Health Observatory 2016-10-28</td>
</tr>
<tr>
<td>5.3 Smoking</td>
<td>Cigarette sales per capita age 15+ (2015) with illicit cigarettes</td>
<td>&lt; 1100</td>
<td>1100 - 1699</td>
<td>≥ 1700</td>
<td>KPMG Project Sun 2016</td>
</tr>
<tr>
<td>5.4 Alcohol</td>
<td>Hours of physical education in compulsory school</td>
<td>≥ 751</td>
<td>750 - 600</td>
<td>&lt; 600</td>
<td><a href="https://webgate.ec.europa.eu/fpfis/mwikis/eurydice/images/0/0f/197_EN_IT_2016.pdf">https://webgate.ec.europa.eu/fpfis/mwikis/eurydice/images/0/0f/197_EN_IT_2016.pdf</a> ; <a href="http://www.vsa.zh.ch">www.vsa.zh.ch</a></td>
</tr>
<tr>
<td>5.5 Physical activity</td>
<td>National programme for teenage girls</td>
<td>Yes</td>
<td>Yes; patient pays significant part of cost</td>
<td>No.</td>
<td>ECDC. Vaccine Schedule Recommended immunisations for human papillomavirus infection 2014.</td>
</tr>
<tr>
<td>5.6 HPV vaccination</td>
<td>SDR/ 100 000 population</td>
<td>&lt; 5</td>
<td>5 - 8</td>
<td>&gt; 8</td>
<td>WHO HIA July 2016</td>
</tr>
<tr>
<td>5.7 Traffic deaths</td>
<td>Proportion of total sales of pharmaceuticals paid for by public subsidy</td>
<td>≥ 70%</td>
<td>65.9 - 50 %</td>
<td>&lt; 50%</td>
<td>WHO HIA database july 2016, EFPIA: The pharmaceutical industry in figures - Key Data 2016</td>
</tr>
<tr>
<td>6.1 Rx subsidy</td>
<td>Is there a layman-adapted pharmacopoeia readily accessible by the public (www or widely available)?</td>
<td>Yes, with a visible and accountable information provider</td>
<td>Yes; but difficult to know who is the information provider</td>
<td>No</td>
<td>HCP research 2010-2016. National Medical Products Agencies. WHO Pharmacopoeia Update.</td>
</tr>
<tr>
<td>6.3 Novel cancer drugs deployment rate</td>
<td>Between registration and inclusion in subsidy system</td>
<td>&lt;150 days</td>
<td>&lt;300 days</td>
<td>&gt;300 days</td>
<td>Patients W.A.I.T. Indicator 2011 and 2012 Reports – based on EFPIA’s databases</td>
</tr>
<tr>
<td>6.4 Access to new drugs (time to subsidy)</td>
<td>TNF-α inhibitors, Standard Units per capita, prevalence adjusted</td>
<td>≥ 300</td>
<td>300 - 100</td>
<td>&lt; 100</td>
<td>IMS MIDAS database July 2015 - June 2016. euromusc.net: Report v5.0 Musculoskeletal Health in Europe (2012), Special Eurobarometer 272 (2007)</td>
</tr>
<tr>
<td>6.5 Arthritis drugs</td>
<td>Statin deployment (ATC code C10A), prevalence adjusted, SU/capita 50+</td>
<td>≥ 150</td>
<td>149 - 50</td>
<td>&lt; 49</td>
<td>IMS MIDAS database, July 2015 - June 2016</td>
</tr>
<tr>
<td>Sub-discipline</td>
<td>Indicator</td>
<td>Comment</td>
<td>Score 3</td>
<td>Score 2</td>
<td>Score 1</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------</td>
<td>----------------------------------------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>6.7</td>
<td>Antibiotics/capita</td>
<td>ATC code J01, DDD/1000 inhabitants per day</td>
<td>&lt; 17</td>
<td>17 – 22</td>
<td>&gt; 22</td>
</tr>
</tbody>
</table>

Table 7.7: Indicator definitions and data sources for the EHCI 2016
7.7.1 Additional data gathering - survey

In addition to public sources, as was also the case for the 2005 - 2014 Indexes, a web-based survey to Patient organisations was commissioned from PatientView, Woodhouse Place, Upper Woodhouse, Knighton, Powys, LD7 1NG, Wales, Tel: 0044-(0)1547-520-965, E-mail: info@patient-view.com. In 2016, this survey included the six Accessibility indicators, two e-Health indicators plus 8 other indicators. The survey can be accessed on https://www.dropbox.com/s/ae670o9pxm63boj/Survey_55014628.pdf?dl=0

A total of 974 patient organisations responded to the survey. The lowest number of responses from any single country was 1 (Albania, Iceland and Montenegro).

Since 2009, the feedback from National Agencies has been a lot better and more ambitious than for previous EHCI editions. For that reason, the responses from the PV survey have been used very cautiously when scoring the indicators. On any indicator, where the HCP has received substantial information from national sources (i.e. information including actual data to support a score), the PV survey results have only been used to modify the score based on national feedback data, when the PV survey responses indicate a radically different situation from that officially reported.

Consequently, the PV survey has essentially been used as a CUTS data source (see section 8.11) only for the waiting time indicators, and for indicator 4.5 Informal payments to doctors.

7.7.2 Additional data gathering – feedback from National Ministries/Agencies

On October 30th, 2016, preliminary score sheets were sent out to Ministries of Health or state agencies of all 35 countries, giving the opportunity to supply more recent data and/or higher quality data than what is available in the public domain.

This procedure had been prepared for during the spring of 2016 by extensive mail, e-mail, telephone contacts and personal visits to ministries/agencies. Finally, feedback responses, in the form of returned “single country score sheets” and/or thorough discussions at personal visits to MoH:s/national agencies, have been had from official national sources.

Score sheets sent out to national agencies contained only the scores for that respective country. Corrections were accepted only in the form of actual data, not by national agencies just changing a score (frequently from Red to something better, but surprisingly often honesty prevailed and scores were revised downwards).

7.8 Threshold value settings

The performance of national healthcare systems was graded on a three-grade scale for each indicator (see more information in Scoring section).

It has not been the ambition to establish a global, scientifically based principle for threshold values to score green, amber or red on the different indicators. Threshold levels have been set after studying the actual parameter value spreads, in order to avoid having indicators showing “all Green” or “totally Red”.

Setting threshold values is typically done by studying a bar graph of country data values on an indicator sorted in ascending order. The usually “S”-shaped curve yielded by that is studied for notches in the curve, which can distinguish clusters of states, and such notches are often taken as starting values for scores. A slight preference is also given to
threshold values with even numbers. An illustration of this procedure can be the scoring diagram for the indicator 1.10 e-Prescriptions:

![E-prescription availability diagram]

Scoring for indicator 1.10. It illustrates the "notches in the S-curve" quite nicely.

Finally, the HCP is a value-driven organisation. We believe in Patient/Consumer Empowerment, an approach that places highest importance on quantitative and qualitative healthcare services. Besides, the HCP also finds it evident that individuals are better fit to make decisions about their health and healthcare than rulings driven by moralistic, religious or paternalistic prejudice.

7.9 “CUTS” data sources

Whenever possible, research on data for individual indicators has endeavoured to find a "CUTS" (Comprehensive Uniform Trustworthy Source). If data on the underlying parameter behind an indicator is available for all or most of the 35 countries from one single and reasonably reliable source, then there has been a definitive preference to base the scores on the CUTS. As CUTS would be considered *e.g.* ECDC data, WHO databases, OECD Health data, Special Eurobarometers or scientific papers using well-defined and established methodology.

Apart from the sheer effectiveness of the approach, the basic reason for the concentration on CUTS, when available, is that data collection primarily based on information obtained from 35 national sources, even if those sources are official Ministry of Health or National Health/Statistics agencies, generally yields a high noise level. It is notoriously difficult to obtain precise answers from many sources even when these sources are all answering the same, well-defined question. For example, in an earlier Index project, it was difficult to ask questions about a well-defined indicator such as "SDR of respiratory disease for males >45 years of age". For one country protesting violently against their score, it took three repeats of asking the question in writing before the (very well-educated) national representative observed that the indicator was
for “males 45+” only, not the SDR for the entire population. It has to be emphasized that also when a CUTS for an indicator has been identified, the data are still reviewed through cross-check procedures, as there have frequently been occasions where national sources or scientific papers have been able to supply more recent and/or higher precision data.

7.9.1 The “Rolls-Royce gearbox” factor

Another reason for preferably using CUTS whenever possible is the same reason why Rolls-Royce (in their pre-BMW days) did not build their own gearboxes. The reason was stated as “We simply cannot build a better gearbox than those we can get from outside suppliers, and therefore we do not make them ourselves”. For the small size organisation HCP, this same circumstance would be true for an indicator where a Eurobarometer question, the WHO HfA database or another CUTS happens to cover an indicator.

7.10 Content of indicators in the EHCI 2016

The research team of the Euro Health Consumer Index 2016 has been collecting data on 48 healthcare performance indicators, structured in a framework of six sub-disciplines. Each of these sub-disciplines reflects a certain logical entity, e.g. Medical outcomes or Accessibility.

For reader friendliness and clarity, the indicators come numbered in the report.

Where possible, CUTS - Comprehensive Uniform Trustworthy Sources - were used; see section “CUTS Data Sources” for more information on this approach, typical for HCP research work.

7.10.1 Patients’ Rights and Information

This sub-discipline is testing the ability of a healthcare system to provide the patient with a status strong enough to diminish the information skew walling the professional and patient.

Why does HCP love this sub-discipline? Because it is a GDP non-dependent indicator family. Even the poorest countries can allow themselves to grant the patient a firm position within the healthcare system; and the 2016 Euro Health Consumer Index is proving this observation again.

There are 12 indicators in this sub-discipline:

1.1 Patients’ Rights based healthcare law

Is national healthcare legislation explicitly expressed in terms of patients’ rights? By law or other legislative act? Are there professional ethical codes, patients’ charters, etc.? This indicator has been in the EHCI since 2005. As the number of countries not having adopted such legislation is now down to three, it might be candidate for replacement in 2016.

Sources of data: http://europatientrights.eu/about_us.html; Patients’ Rights Law (Annex 1 to EHCI report, used as starting material); updates through European
1.2 Patients' Organisations involved in decision making

Do patient organisations have the right to participate in healthcare decision making? Sometimes we find that patient's organisations are welcomed to get involved, sometimes they do it by law, sometimes they do it only informally, but usually, sometimes only formally without a real participation, sometimes not at all.


1.3 No-fault malpractice insurance

Can patients get compensation without the assistance of the judicial system? Does the compensation prerequisite proving who among the medical staff made a mistake? Each year, the HCP research staff is meeting high healthcare officials who have never heard of no-fault malpractice system, such as that put in place essentially in the Nordic countries. However, since 2009, there has been clear development in this area in a number of countries.

Source of data: Swedish National Patient Insurance Co. (All Nordic countries have no-fault insurance); www.hse.ie ; www.higa.ie . National healthcare agencies, web-based research, journals search. Non-CUTS data.

1.4 Right to second opinion

As in other areas of human life, there are not many questions and conditions with only one right answer, in medicine also. Therefore, do the patients have the right to get the second opinion, without having to pay extra? Is it a formal right, but unusual practice, or well-established institute?

As can be seen, with some difficulty, by comparing the 2014 and 2016 graphs (below), is that patient awareness of the availability of a second opinion is indeed increasing in many European countries.

Countries where this right exists on paper, but where patient organisations reveal a low degree of knowledge of its existence, have been awarded a Yellow score instead of the Green, which the formal situation would have given.

1.5 Access to own medical record
Can patients readily get access to, and read, their own medical records? Hard to believe, at some places in Europe, the patient's personal data and integrity is so protected, that she cannot access her own medical record. This is remarkable, as the EU Data protection directive is very clear on the fact that the patient should have this right by law. Elsewhere, she cannot access it either, but at least she is not being told it is for her own good. However, in recent years, this situation seems to have improved significantly in a number of countries!

Even though patient records are supposed to be available to individual patients, patient awareness of this is low in several countries.


1.6 Register of legit doctors

Can the public readily access the information: "Is doctor X a bona fide specialist?" To qualify, this has to be a web/telephone based service. Yellow pages do not score Green – with an exception for Luxembourg, where the chapter on physicians is yearly reviewed and approved by the Ministry of health. This is a very easy and cheap service to implement, but still it is very difficult to find such sources of information.


1.7 Web or 24-7 telephone healthcare info with interactivity

Simple description of this indicator used in previous years’ editions remains the same in 2013: Information which can help a patient take decisions of the nature: “After consulting the service, I will take a paracetamol and wait and see” or “I will hurry to the A&E department of the nearest hospital” The most comprehensive service of this kind is
the British NHS Direct. In 2016, several countries have developed decentralized solutions such as “round-the-clock” primary care surgeries, which offer the same service.


1.8 Cross-border care seeking financed from home

The directive on the application of patients’ rights to cross-border healthcare was decided on 2011-03-09. EU countries had until 25 October 2013 to pass their own laws implementing the Directive. Therefore, the criteria for scores on this indicator were tightened considerably compared with previous ECHI editions. At the time of publication of this report (January 2017), some little progress seems to have happened since autumn 2013.

For the first time, the European Commission has published data on payment streams for citizens receiving care in another EU country (Figure below). According to the data reported to the commission, Austria was the only country where these costs in 2014 exceeded EUR 1/capita. Data on some countries was missing, such as for The Netherlands and Malta, who both have an established tradition of allowing care outside the country.

As was predicted in the EHCI 2015 report, penetration of the Dutch observation that “free access to cross-border care will not exceed 1% of healthcare budgets” seems to require assisted delivery.

Figure 7.10.1.8 MEMBER STATE DATA on cross-border healthcare following Directive 2011/24/EU, Year 2015, European Commission.

Sources of data: MEMBER STATE DATA on cross-border healthcare following Directive 2011/24/EU, Year 2015, European Commission. National healthcare agencies.
1.9 Provider catalogue with quality ranking

In 2005, Dr. Foster of the UK was the single shining star on the firmament of provider (hospital) listing, where patients could actually see which hospitals had good results in term of actual success rates or survival percentages. Today, that has evolved into “NHS Choose and Book”\(^{12}\).

In 2016, there are still only a few more examples, where the Health Consumer Powerhouse believes that the most notable was the Danish [www.esundhed.dk/sundhedskvalitet/Pages/default.aspx](http://www.esundhed.dk/sundhedskvalitet/Pages/default.aspx), where hospitals were graded from ★ to ★★★★★ as if they were hotels, with service level indicators as well as actual results, including case fatality rates on certain diagnoses. Unfortunately, this website no longer contains actual treatment results.

In 2016, the British NHS Choices remain the standard European qualification for a Green score. The “best clinics” published by the weeklies LePoint/Figaro in France gives a Green in 2016, as the HCP survey indicated a high degree of familiarity with that among patients. Also, in 2016 Estonia, The Netherlands, Norway, Portugal and Slovakia score Green. Germany, scoring Yellow in 2012, now scores Green (again) as public access to this information has been restored. Sweden has the information available in a 400+ page book, but that can hardly be described as easily accessed by patients.

![Knowledge about availability of hospital "catalogue" showing treatment outcomes](image)

Figure 7.10.1.9 The Yellow scores for Iceland and Malta are awarded not to discriminate against islands having only one real hospital each.


1.10 EPR penetration

Percentage of GP practices using computer for storage of individual patient data and communication with other parts of the healthcare system. Finally in 2016, 20 years later

\(^{12}\) [www.chooseandbook.nhs.uk](http://www.chooseandbook.nhs.uk)
than what should have been, this is becoming the norm in Europe! Among countries now scoring Green on this indicator are FYR Macedonia and Serbia, both on the merits of installing the Macedonian IZIS e-health system.

Sources of data:
http://www.europartnersearch.net/ist_communities/indexmapconso.php?Se=11;
www.icgp.ie; Commonwealth Fund International Health Policy Survey of Primary Care Physicians“Benchmarking ICT use among GP:s in Europe”; European Commission, April 2008; study made by Empirica, Bonn, Germany (p.60), Gartner Group. CUTS data.

1.11 Do patients have access to on-line booking of appointments?

The supply/demand ratio for specialist appointments or major surgery is very similar to that of hotel rooms or package holidays. There is no real reason why patients should not be able to book available “slots” at their convenience. This exists rather sparingly in Europe; in 2009, one of the only two Green scores went to Portugal, where “4 million people in the Lisbon region” were said to have access to this service. In 2016, thirteen countries have made this service available to sizeable groups of citizens – quite an improvement (2013: 9 countries), but little has happened since 2014! As is illustrated by the Macedonian example, this service has the potential to more or less eradicate waiting lists from a healthcare system! Among countries now scoring Green on this indicator are FYR Macedonia and Serbia, both on the merits of installing the Macedonian IZIS e-health system.

1.12 e-Prescriptions

HCP survey question:
“Can your country’s patients collect drugs from a pharmacy with the prescription being sent electronically? [This is known as ‘e-prescriptions’, and no paper prescription is issued.]”

1. Yes, this facility is widely available.
2. It does exist, but is only offered by a few pioneering doctors/clinics/hospitals.
3. No (or it is very rare).

Figure 7.10.1.12 Survey responses to the above question.

Croatia and the Nordic countries are leading Europe. Considering that an e-Prescription is just a very standardised piece of e-mail, the rate of progress is depressingly slow. Among countries now scoring Green on this indicator are FYR Macedonia and Serbia, both on the merits of installing the Macedonian IZIS e-health system.

Sources of data: Survey commissioned by HCP from Patient View 2016. "The set-up of guidelines in support of European e-Prescription interoperability (2011-2013)", Empirica, Bonn); National healthcare agencies.

7.10.2 Waiting time for treatment

2.1 Family doctor same day access

Testing a very reasonable demand: Can patients count on seeing a primary care doctor today, on the _only_ indication “The patient suffers from the opinion that he needs to see a doctor”? 
Figure 7.10.2.1a Survey responses to the question: “Can your country’s patients see their primary care doctor that same day (with or without an appointment)?” 1.0 = all yes; 3.0 = all "normally not". In Serbia, primary care centres are open for “drop-in” patients 24/7; the negative bias of patient responses in Luxembourg, Serbia and The Netherlands is unexplained.

The responses on this indicator basically show that there is no logical explanation for waiting times in primary care; the findings seem to be randomly placed in the order of national wealth; there is no correlation with financial matters (GDP or healthcare spend per capita) nor the range of services provided, nor the density of primary care network (see graph below). In some rather unexpected countries, the GP even has the obligation to answer the phone to every patient registered in his practice 24 hours per day, 7 days a week.

Figure 7.10.2.1b Doctors per 100 000 people (broad bars) and Number of outpatient contacts per person (narrow bars). As the graph shows, there is very poor correlation between doctors per
*capita* and Access to doctor. There are some culture streaks: the Nordic countries (green broad bars) only want patients to see a doctor when really sick. Swiss and Portuguese do not disturb their doctors too much, either. The very low numbers of visits per doctor in Cyprus or Greece (which has by far the highest number of doctors *per capita*) could possibly be under-reporting of visits for tax evasion reasons. The Austrian system seems to share the productivity problem of the Nordic countries.


### 2.2 Direct access to specialist

Can patients see a specialist without first having to gain a referral from a primary-care doctor?

This indicator might be the most disputed of all in the history of HCP indexes. However, EHCI research does not take religious beliefs into consideration, be they moslem, catholic or the Faith in GP Gatekeeping. Consequently, the indicator has been kept since 2005, and seems to confirm the notion that "no significant effects of gatekeeping were found on the level of ambulatory care costs, or on the level or growth of total health care expenditure".


### 2.3 Major non-acute operations <90 days

What is the interval between diagnosis and treatment for a basket of coronary bypass/PTCA and hip/knee joint? It is difficult to avoid the observation that countries, which do have official waiting time statistics (Ireland, Sweden, UK etc), this is in itself a not very flattering circumstance. Countries such as Germany, where waiting times tend to vary in the 2 – 3 weeks range, have never felt the urge to produce waiting time data, for principally the same type of reason that Singapore has less snow-ploughs than Helsinki.

As the graph shows, this is one of the few EHCI indicators, where traces of the financial crisis show up: waiting times for (expensive) elective surgery seemed increase slightly between 2009 and 2013, most notably in some countries severely hit by the crisis. However, this effect, if not an artefact, was quite modest, and 2014 seemed to show improvement in many countries. Unfortunately, the data indicates that this improvement seems not to last into 2016.

Survey results for small countries should be taken with caution due to the limited number of survey responses! Among countries now scoring better on this indicator is Serbia on the merits of installing the Macedonian IZIS e-health system.

Sources of data: Patients’ Perspectives of Healthcare Waiting times in Europe; survey commissioned by HCP 2015. National healthcare agencies. Non-CUTS data.

### 2.4 Cancer therapies < 21 days

This indicator measures the time to get radiation/chemotherapy after decision to treat (DTT). The time limit for a Green score is, and should be, much tighter for cancer treatment than for elective surgery. Encouragingly, the general level of accessibility to cancer care is superior to that of elective surgery also when the much tighter cut-off for a Green score (21 days vs. 90 days) is taken into consideration.

The Patient Organisation survey commissioned by HCP had the same logic as for elective surgery (above) with an average response score of 1.0 for cancer treatment meaning
essentially “everybody receives treatment within three weeks” to 3.0 meaning “everybody waits more than three weeks”.

Interestingly this indicator shows a similar tendency as waiting times for elective surgery: an austerity-induced (?) slight increase of waiting time for these costly treatments between 2009 and 2013, and a minor improvement in 2014, which continues into 2015.

<table>
<thead>
<tr>
<th>Year</th>
<th>Average cancer wait responses</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>1.692</td>
</tr>
<tr>
<td>2012</td>
<td>1.789</td>
</tr>
<tr>
<td>2013</td>
<td>1.871</td>
</tr>
<tr>
<td>2014</td>
<td>1.833</td>
</tr>
<tr>
<td>2015</td>
<td>1.775</td>
</tr>
</tbody>
</table>

Among countries now scoring better on this indicator is Serbia on the merits of installing the Macedonian IZIS e-health system, and due to a 50% increase in radiation treatment capacity during 2016.


### 2.5 CT scan < 7 days

As a representative for waiting times for advanced diagnostics was chosen Time to get a CT scan after referring doctor’s decision. There proved to be some difficulty making respondents (in national healthcare agencies) not answer in terms of “acute” or “non-acute” examinations. Again, is has to be emphasized that waiting times for a CT scan is both poor service quality and also increases costs, not saving money, as the procedure of keeping track of patients for weeks/months is by no means costless, and the examination itself is if anything cheaper if the patient (and the care provider) has the underlying cause fresh in their minds.

The Patient Organisation survey commissioned by HCP had the same logic as for elective surgery (above) with an average response score of 1.0 for a non-acute CT scan meaning essentially “everybody receives an examination within one week” to 3.0 meaning “everybody waits more than three weeks”.

Among countries now scoring better on this indicator is Serbia on the merits of installing the Macedonian IZIS e-health system.
Survey responses non-acute CT scan waiting times. < 7 days for a Green might seem tight, but there is no real life reason to have longer waits. Albanian and Icelandic scores were modified from national data in 2014 – patient responses seem to have confirmed that in 2016.


### 2.6 A&E department waiting time

New indicator in 2013. HCP patient organisation survey question:

"Which of the following would be the more TYPICAL waiting time in your country for a visit to the Accident and Emergencies department of a hospital? [Please regard “waiting time” as the period between arrival at the hospital door and when a doctor starts treating/attending to your problem.]

1. Typically LESS THAN 1 hour.
2. Typically MORE THAN 1 hour, but LESS THAN 3 hours.
3. Frequently MORE THAN 3 hours."

It is probably not a coincidence that for countries scoring low on Accessibility, such as Sweden, the UK and Ireland, this spills over into long A&E waiting times!

In January 2016, the Swedish National Investigator of healthcare system efficiency actually suggested compulsory referral to access a hospital A&E department! Referral from whom?
7.10.3 Outcomes

The Outcomes sub-discipline assesses the performance of different national healthcare systems when it comes to results of treatment. The healthcare professionals sometimes tend to think about the healthcare systems predominantly in the terms of outcomes – saying that what really counts, is the result. We do agree to some extent, and this is reflected in the weight attributed to the outcomes sub-discipline indicators.

3.1 Decrease of CVD Death Rates

Data availability on the Acute Heart Infarct (AMI) in-hospital case fatality indicator is shockingly fragmented and incoherent over Europe.

For this reason, that indicator has been replaced since the EHCI 2014 by the indicator “Inclination of the long-time trend line for ischaemic heart disease Standardized Death Rates”. Before the turn of the millennium, it was more or less regarded as axiomatic that CVD was the main cause of death in Europe. Part of this was bad reporting; as death frequently occurs when the heart stops beating, heart failure was often routinely put as cause in death certificates. One such example was Bulgaria, which in the early 2000’s reported CVD as cause of death in 66 % of deaths.

Improvement of cardiac care has significantly changed this situation, as is shown in the Table below\textsuperscript{14}.

\textsuperscript{14} Townsend et al., Cardiovascular disease in Europe: epidemiological update 2016”, European Heart Journal. doi:10.1093/eurheartj/ehw334
France reached the point, where cancer became a more frequent cause of death than CVD as early as 1988 – that France has a very low CVD rate has been known for 200 years\textsuperscript{15}. By 2000, this was achieved also by Spain, with 10 more countries following suit up until 2013.

That this change has to be attributed to improved cardiac care is proven by the WHO\textsuperscript{16}. The lifestyle risk factors driving diabetes are largely the same as those driving CVD. An assumption that improved CVD care would not be due to improved healthcare requires the rather drastic conclusion that WHO and world diabetologists are talking through their collective hats!

The actual indicator data is the *steepness of the long-time trend line inclination*. This calculation has been done on the logarithmic values of the SDR numbers to compensate for the fact that *e.g.* France starts the comparison at an SDR around one 6\textsuperscript{th} of some CEE countries (see graph below).

\begin{table}
\centering
\begin{tabular}{|l|c|c|c|c|c|}
\hline
Country & Latest year & Men No of deaths Cancer & Men No of deaths CVD & Year of change & Women No of deaths Cancer & Women No of deaths CVD & Year of change \\
\hline
Belgium & 2012 & 15,920 & 14,299 & 2006 & 7613 & 6654 & 2010 \\
Denmark & 2012 & 8226 & 6442 & 2010 & 7613 & 6654 & 2010 \\
Italy & 2012 & 99,794 & 99,661 & 2012 & 5507 & 5217 & 2012 \\
Israel & 2013 & 5455 & 4819 & 2009 & 5507 & 5217 & 2012 \\
Luxembourg & 2013 & 566 & 523 & 2010 & 5507 & 5217 & 2012 \\
The Netherlands & 2013 & 23,766 & 18,026 & 2004 & 5507 & 5217 & 2012 \\
Norway & 2013 & 5788 & 5630 & 2013 & 5507 & 5217 & 2012 \\
Portugal & 2013 & 15,746 & 13,981 & 2009 & 5507 & 5217 & 2012 \\
Slovenia & 2010 & 3245 & 3071 & 2007 & 5507 & 5217 & 2012 \\
\hline
\end{tabular}
\caption{European countries where the number of cancer deaths exceeds the number of deaths from CVD for men and women}
\end{table}

\footnotesize
\textsuperscript{15} Blake, S. *Clinical and Pathological Reports* (monograph), Newry, N. Ireland (1818)

\textsuperscript{16} \url{www.who.int/diabetes/global-report/en/}
Source of data: WHO Health for All database, July 2016. CUTS data.

### 3.2 Decrease of stroke death rates

Using the same logic as for CVD finally made it possible in 2014 to introduce a long wanted indicator for the largest cause of death after CVD and cancers; stroke:

Source of data: WHO Health for All database, July 2016. CUTS data.
3.3 Infant deaths

Infant mortality rate is the number of infants dying before reaching one year of age, per 1,000 live births in a given year. In the well developed countries the increased infant mortality occurs primarily among very low birth weight infants, many of whom are born prematurely; in Europe, very low birth weight infants probably account for more than half of all infant deaths. In Europe, with infant deaths normally counting below 6/1000, good check-ups during pregnancy and access to state-of-the-art delivery care are probably the key factors behind attaining really low numbers. Luxembourg and Iceland have the lowest infant death rate on Earth, less than 2/1000.

This indicator might be the best single indicator, which could be used to judge the overall quality of a healthcare system. It is interesting to note that this indicator seems totally resilient to effects of financial crises; infant mortality numbers have been, and still are, steadily improving since 2005! The Green/Yellow/Red cut-offs have been kept the same since the start of the EHCI. The number of countries scoring Green has increased from 9 in 2006, to 24 in 2016.

A particularly impressive improvement is shown in Latvia, where infant mortality did go from 6.2 to 3.9 in two years! In the EHCI 2016, also the UK, for the first time, joins the group of countries scoring Green.


The reader is urged to save this passage, if interested. In order to preserve the distinctiveness of the EHCI, the G/Y/R cut-offs will presumably be sharpened in 2017.

Sources of data: WHO Europe Health for All mortality database July 2016, latest available statistics. Later data for some countries reported by national bodies. CUTS data.

3.4 Ratio of cancer deaths to incidence 2012
The EHCI 2008 indicator on cancer outcomes was the more conventional 5-year survival rates of cancer (all types except skin). As no more recent data than EUROCARE-4, (patients diagnosed 1995 – 1999) data was available in the spring of 2012, the very comprehensive paper by J. Ferlay et al, listing cancer incidences and cancer deaths in 2008 for all 34 countries was chosen as 2012 indicator data. In this indicator, a ratio of less than 0.4 for Deaths/Incidence, would in principle be equal to a survival rate > 60%.

As there was a 16-month interval between the EHCI 2012 and EHCI 2013, fate arranged that Ferlay et al published a paper based on the same data for the year 2012 in time for this report. This means that the data in the graph below shows the situation in 2008 and 2012, i.e. two years “straddling” the financial crisis. Unfortunately, this data is still in 2016 the most recent comprehensive cancer mortality data.

As this report has observed numerous times, it is very difficult to trace any effects of financial austerity on Outcomes of treatment of serious diseases! Cancer survival keeps improving, also in countries known to be hit particularly hard by austerity.


### 3.5 Potential Years of Life Lost

This indicator measures Years lost per 100,000 population 0-69, all causes of death. Potential Years of Life Lost (PYLL), used by the WHO and OECD, take into account the age at which deaths occurs by giving greater weight to deaths at younger age and lower weight to deaths at older age.

Potential Years of Life Lost are calculated from the number of deaths multiplied by a standard life expectancy at the age at which death occurs. PYLL is preferred as an indicator for the EHCI over and above the popular “Healthcare Amenable Deaths”, as that indicator automatically gives low values to states with a low CVD death rate, such as the Mediterranean states, most obviously France.
Source of data: WHO Detailed Mortality Database, excerpt October 2016. Cut-offs between Green, Yellow and Red have been kept the same as in previous years for longitudinal comparison. CUTS data.

### 3.6 MRSA infections

This indicator measures the percentage of hospital-acquired strains being resistant. The aim of this indicator is to assess the prevalence and spread of major invasive bacteria with clinically and epidemiologically relevant antimicrobial resistance. As in the previous year’s indexes, The European Antimicrobial Resistance Surveillance System (ECDC EARS-net) data is used. The data is collected by 800 public-health laboratories serving over 1300 hospitals in 31 European countries.

The share of hospital infections being resistant has been uncannily stable over time in many countries, which is slightly surprising: One would think that either a country has the problem fairly well under control (such as the Nordics and The Netherlands) or one would expect fluctuation over time. Why countries like Germany and France could have this rate stable at just over or under 20 % remains a mystery. Since 2012, Germany does show a significant reduction.

The real improvement has been achieved in the British Isles: through a very dedicated effort, both Ireland and the U.K. have brought their resistance rates down from 40 – 45 % in 2008 to less than 20 % (Ireland) and less than 15 % (UK).
3.7 Abortion rates

Introduced in the EHCI 2013.

The scoring of this indicator is somewhat complex. The scores are fundamentally based on the principle that free, legally defined abortion should be available for women in any country\textsuperscript{17}. At the same time, using abortion as a contraceptive must be regarded as very undesirable. This was illustrated by Russia, where the abortion rate in the early 1990’s was in excess of 200 abortions per 100 live births, but today is coming closer to the rest of Europe at 55 per 100. Remnants of the same practice can be discerned in former Warsaw pact countries (see Graph below). Depressingly, Sweden still belongs to that same group.

There are four countries in Europe, where free abortion rights do not exist: Cyprus, Ireland, Malta and Poland. These countries have been given the unique Purple score (= 0 points), even though new Irish legislation allows for abortion in extreme circumstances and subject to external verdict. It has been well known for centuries that stigmatizing or banning abortion results in tragedies such as the female dentist, who died in a Galway hospital because doctors did not dare/want to perform an abortion on her (already dying) foetus. Legal bans do not prevent abortions but rather turns them into a major health risk, forcing women to go abroad or having an abortion under obscure, insecure conditions. The latter affects almost solely women in socioeconomically deprived circumstances. In Poland, there has recently been political discussion about restricting the right to abortion even further.

\textsuperscript{17}European Parliament REPORT on Sexual and Reproductive Health and Rights, (2013/2040(INI)), Committee on Women’s Rights and Gender Equality, Rapporteur: Edite Estrela, 2013-09-26
Austria does not ban abortion, but it is not provided by public hospitals, which results in defunct abortion statistics. Luxembourg also has no abortion statistics, presumably because women discreetly often have abortions in neighbouring countries.

![Abortion statistics graph]

Source: WHO Health for All database, July 2016. Cuts data.

### 3.8 Depression

Since 2005, HCP has wanted to introduce an indicator on quality of psychiatric care. Due to substantial methodological and definitions problems, resulting in gross inconsistencies of data, we rejected the usual indicators as psychiatric beds per population, mental disorders hospitalisation, drug sales and many others. The decline of suicide in a ten year period, e.g. since 1995, somehow returned, every year, to the expert panel’s working sessions. But, adding to uncertain data reliability, there was a practical problem to solve: taking into account the very significant peak of suicide in Eastern European countries in 1991-1995, how to make the indicator fair for the whole European region?

In 2008, following long and vivid discussions, the indicator “inclination of e-log line for suicide SDR:s 1995 – l.a.” was introduced, being fully aware of its interpretative limitations.

In 2012, it became evident that general improvement in living conditions, particularly in CEE, and later the effects of the financial crisis in countries such as Greece outweighed the effects of psychiatric care on suicide rates. In the intense search for a relevant indicator on mental health, we finally elected to combine (arithmetic average) the 5 questions in the table below from a Special Eurobarometer on Mental Health:

<table>
<thead>
<tr>
<th>How often during the past 4 weeks ...?</th>
<th>How often during the past 4 weeks ...?</th>
</tr>
</thead>
<tbody>
<tr>
<td>% &quot;all the time&quot; + % &quot;most of the time&quot;</td>
<td>% &quot;never&quot; + % &quot;rarely&quot;</td>
</tr>
<tr>
<td>Have you felt happy</td>
<td>Have you felt calm and peaceful</td>
</tr>
<tr>
<td>Have you felt so down in the dumps that nothing could cheer you up</td>
<td>Have you felt downhearted and depressed</td>
</tr>
<tr>
<td>Have you felt particularly tense</td>
<td></td>
</tr>
</tbody>
</table>
For Norway, not being included in the Eurobarometer, a national study directly comparing with the same Eurobarometer was found. Unfortunately, for EHCI 2016 it was not possible to find more recent data.


3.x COPD mortality (not included in the EHCI 2016 scoring)

Chronic Obstructive Pulmonary Disease (COPD) is the 4\textsuperscript{th} largest cause of death in most European countries (after CVD, cancer and stroke).

Data on COPD diagnostics are shaky. In many countries, there is a lack of separation of COPD and asthma diagnoses. When the HCP produced the Nordic COPD Index 2010\textsuperscript{18}, a leading pulmonary expert on the Index Expert Panel actually suggested using smoking prevalence as a proxy for COPD prevalence! (Unfortunately, smoking prevalence data are also shaky.)

For the EHCI 2016, an attempt was made to estimate COPD mortality by starting with the total mortality of “Diseases of the respiratory system”, and subtracting the numbers for pneumonia and influenza (conditions responsible primarily for the death of the old and infirm). The result is illustrated in the Graph below:

As several countries with very high cigarette smoking prevalence end up getting a Green score using this methodology (the discrepancy is even greater when looking at official COPD death numbers), it was decided only to include this indicator in the report to show an interesting phenomenon – it is not counted into the national scores.

Also intriguing is why the British Isles show such high respiratory disease numbers. Their weather, particularly in the more populous parts, is not that bad!

\textsuperscript{18} www.healthpowerhouse.com
### 7.10.4 Range and reach of services provided

#### 4.1 Equity of healthcare systems

The simple indicator “What % of total healthcare spend is public?” was introduced in 2009 as a measure on equity of healthcare systems. Switzerland was (and is) judged to be a victim of the same kind of definition problems as pre-reform (2006) Netherlands, where on formal grounds a large part of the common health insurance was reported as private spend, and is given a Green score.

In some countries, the public share of healthcare financing decreased slightly during the financial crisis, most notably in Ireland. According to official data, Greece is not in that group, which is interesting.

The WHO data were cross-checked vs. data from “Eurostat Self-reported unmet needs for medical examination by sex, age, detailed reason and income quintile”. This resulted in a Red score for Romania.

![Public share (% of total healthcare costs)

Source: WHO HfA, July 2016](image)

Sources of data: WHO HfA database, July 2016. Eurostat: Self-reported unmet needs for medical examination by sex, age, detailed reason and income quintile. CUTS data.

#### 4.2 Cataract operations per 100 000 age 65+

Surgical procedures by ICD-CM, Cataract surgery. Total procedures performed on patients of all ages, but divided by 100 000’s of population over 65. Few cataracts are performed on patients under 65, and age-separated data is not available.

Cataract operations per 100 000 total population has been continuously used in previous EHCI editions as a proxy of the generosity of the healthcare systems to provide non-lifesaving care aimed at improving the quality of life of the patient. Cataracts have been selected because they are relatively inexpensive and provide large improvement in patient Quality of Life, thus being fairly independent on GDP/capita of a country. Since 2008, the indicator has been age-adjusted following a suggestion made by Irish officials.
(which is not surprising, as the non-age standardized indicator would have disadvantaged Europe’s youngest nations; Macedonia, Ireland and Romania).

This indicator did prove unexpectedly complicated. Some data faithfully reported to and quoted by the OECD turned out to be totally off the mark: the OECD Health Data number for Belgium used to be 204 868 cataract operations/year. Considering that an annual cohort of Belgians 65+ is not much greater than 100 000, that number would mean that eventually every single elderly Belgian would have cataract ops on both eyes! The Belgian Ministry of Health agreed about the absurdity of the number, and rapidly reported what they considered the accurate number: 107 056 operations, a number the research team could believe! This awkward procedure puts the searchlight on the fact that very strange data can be accepted in official sets of data, as it looks without further consideration.

Belgian data has lately been corrected also in international databases.

Sources of data: OECD Health Data 2016, WHO HfA database July 2016, WHO Prevention of Blindness and Visual Impairment Programme, European Community Health Indicators, National healthcare agencies. Very non-CUTS data!

### 4.3 Kidney transplants per million population

This indicator measures procedures per million population. There is a commonly encountered notion that this number is greatly influenced by factors outside the control of healthcare systems, such as the number of traffic victims in a country. It must be judged that the primary explanation factors are inside healthcare, such as “the role and place of organ donation in anaesthesiologists’ training”, “the number of Intensive Care Unit beds p.m.p.”, the organisation of healthcare to optimise the handling of organs, etc. Experience tells that well-implemented national strategies can significantly increase donations.
The relatively low transplant rates for Switzerland, and particularly Germany, support that transplant rates are governed by cultural factors rather than national wealth.

Sources of data: Council of Europe (EDQM) Newsletter INTERNATIONAL FIGURES ON DONATION AND TRANSPLANTATION 21 (2016), Ministries of Health direct communication. CUTS data.

### 4.4 Is dental care included in the public healthcare offering?

In past years, the very simple indicator “What percentage of public healthcare spend is made up by dental care?” was selected as a measure of affordability of dental care, on the logic that if dental care accounts for close to 10 % of total public healthcare expenditure, this must mean that dental care is essentially a part of a fair public healthcare offering.

2016 data on this indicator comes mainly from Eurostat self-reported data on: “Unmet needs for dental examination”.

---

---
4.5 Informal payments to doctors

Mean response to question: "Would patients be expected to make unofficial payments?" with range of answers: plain "No!", "Sometimes, depends on situation" and "Yes, frequently". The indicator was first introduced in 2008. As an informal payment was considered any payment made by the patient in addition to official co-payment. That survey on informal payments was the first cross-European survey done ever on this problem, and was repeated in 2009 and 2012 – 2015, with highly compatible results compared with 2008.

In 2015, the countries fell in three fairly distinctive groups, making the R/Y/G scoring natural. These results have also been remarkably stable over the years, e.g. with Portugal and Spain scoring Green, and France and Austria scoring Yellow. This is why the EHCI keeps the Yellow scores for these two countries, despite rather violent protests from the national medical chambers.
Sources of data: Survey commissioned from Patient View by HCP 2015. National healthcare agencies. Non-CUTS data.

4.6 Long term care for the elderly

This indicator looks into what is often referred to as a historic challenge for Europe: how to care for the rapidly aging population? The result reflects not only today’s investment in care, and accordingly, the future needs for coping with the growing demand. It also shows the imbalance between public caring and unofficial contributions. It can be assumed that in all countries elderly people are given some kind of attention; should the family and informal networks take the burden or can they trust public systems to assist?

This is a notoriously difficult indicator, not least as long term elderly care is reported under social services rather than under healthcare in many countries.

The HCP team made considerable effort to find more outcomes-related data. Since 2012, we have had to settle for “# of nursing home and elderly care beds per 100 000 population 65+”.
4.7 Share of dialysis done outside of clinics

Dialysis is necessary for the survival of patients with renal and liver malfunctions. There are a few ways to perform this treatment. Dialysis performed as clinic-bound dialysis (hemo-dialysis: HD) has several drawbacks:

   a) Treatment episodes are usually 3x4 hours per week, which is a far cry from the 168 hours per week of functioning healthy kidneys. Patients who do home dialysis (Peritoneal dialysis; PD, or HD in the home) frequently treat themselves up to 7 x 6 hours, i.e. nightly, with better treatment outcomes.

   b) Patients have great difficulties keeping a job, as dialysis requires presence in a clinic essentially three days a week.

   c) Dialysis in a clinic is much more expensive, typically kEUR 50 – 60 per patient per year.

It seems that a low rate of home dialysis is not mainly due to preferences/capabilities of patients, but rather due to either

   i. Lack of professionalism of local nephrologists (there are centres of excellence around which close to 50% of dialysis patients dialyse themselves in the home), or

   ii. Greed (clinic dialysis is very profitable for the clinics).

For these reasons, a high share of home dialysis gives a Green score on this indicator.
4.8 % of births by Caesarean section

Caesarean sections are associated with an increased risk of maternal death and puerperal complications, so use should be restricted to a few well-defined indications such as dangerous placental or foetal position. The World Health Organisation estimates that no more than 10 – 15% of deliveries are associated with a medically justifiable reason for a Caesarean section.

In scoring, it has been assumed that high Caesarean rates are an indication on poor prenatal support and poor baby delivery services – consequently, a high Caesarean rate has been given a Red score. The general recommendation is that a woman should not have more than two Caesarean deliveries, which strongly indicates that complete recovery cannot be expected. Also, the typical French practice for getting back in shape after a delivery – post-natal physiotherapy – seems both more humane and more economical than invasive surgery.

This way of delivery can be medically important and should of course be available. But HCP suspects that Caesarean section may camouflage a lack of good information and support before delivery as well as lack of access to pain control or doctors wanting to schedule births.

The highest rates of Caesareans in the world are found in Cyprus, Greece and Latin America (Brazil and Venezuela also close to or above 50 %).

Please note in the graph below that even though a Caesarean is costly, there is definitely no positive correlation between national wealth and high Caesarean rates; rather the reverse!

Source: WHO Health for All database, July 2016. CUTS data.
7.10.5 Prevention

5.1 Infant 8-disease vaccination

Percentage of children vaccinated (Diphtheria, tetanus, pertussis, measles, poliomyelitis, rubella, hepatitis B and haemophilus influenza B, arithmetic mean).

Vaccination is generally regarded as cost-effective prevention, which is reflected by several less wealthy countries scoring Green.

5.2 Blood pressure

This indicator measures the % of adult population registering high blood pressure (> 140/90).

As is evident from the graph, hypertension in Europe is not associated with high standard of living, but rather a combination of lifestyle factors (CEE food, smoking and drinking habits) and a lack of treatment tradition – hypertension treatment is not expensive.

It seems that the UK and Ireland are following the North American example of actively treating hypertension, as well as high blood lipids!

Source: WHO Global Health Observatory, extracted October 2016. CUTS data.

5.3 Smoking prevention

The Tobacco Control Scale (TCS) has been used as a measure of countries’ efforts on smoking prevention. It is made up by six indicators: Price (30), Public place bans (22), Public information campaign spending (15), Advertising bans (13), Health warnings (10) and Treatment (10). Numbers in parentheses denote the weight (contribution of a Full score to the TCS maximum total of 100).

As the TCS has not been updated since its 2012 data, the EHCI 2016 uses actual cigarette sales per capita on this indicator. Due to high shares of duty-free and illicit cigarettes, the consumption of some countries, most probably Norway and the UK, are often underestimated. Project Sun, carried out by audit firm KPMG, claims to have compensated for these sales.
5.4 Alcohol consumption

Unlike cigarette smoking, alcohol as a risk factor is not always harmful. It has been shown in numerous studies that a modest alcohol intake (the equivalent of one glass of wine per day for women, and 1 – 2 glasses per day for men) reduces the risk of death from CVD enough to result in a lower mortality than for total abstainers.

On the other hand, drinking vast quantities of alcohol on single occasions ("binge drinking") is a known risk factor for CVD, and also for some cancer forms. This seems particularly true for binge drinking involving hard liquor consumption.

For these reasons, this indicator is based on “total alcohol consumption (litres of pure alcohol), binge drinking adjusted”. The adjustment is made by multiplying the nominal consumption by (1 + percentage of population having had ≥ 5 drinks on their latest drinking occasion).

Note the low alcohol consumption of the two countries having the highest share of moslem population!

Source: KPMG Project Sun, 2016.
5.5 **Physical activity**

Physical exercise is beneficial to reduce risk for illness for a vast spectrum of diseases. There is statistics on parameters such as "number of hours of jogging or similar per person per week" for many countries. However, the radio noise level of this data is probably quite high. Also, this is a parameter which is very difficult for any decision makers to change for a significant part of a population within a reasonable time frame.

Therefore, the physical exercise parameter chosen for the EHCI 2016 is "number of hours of physical exercise in compulsory school" (counting a maximum of 10 school years), according to nationally set standards. This is a parameter that *e.g.* a government has the power to change.

The reason for a score switch from Red to Yellow between Finland and Malta is that cut-off values have been retained the same for several years.
5.6 HPV vaccination

In recent years, many countries have included HPV vaccination for girls in their lower teens in national vaccination programmes. This indicator has been scored as:

- **Green**: National programme for HPV vaccination in place, free of charge to patient.
- **Yellow**: National programme for HPV vaccination, patient pays (significant part of) cost.
- **Red**: No national HPV vaccination programme.

It would have been desirable to measure the degree of coverage of these vaccination programmes – such data is not yet available.


5.7 Traffic deaths

This was a new prevention indicator introduced in 2014. It is not really healthcare dependent, but nevertheless amenable to decision making by humans. Traffic deaths, and also personal injuries due to traffic accidents, have been much reduced over the last 30 – 40 years in almost all countries in Europe. There still are large variations between European countries, as is shown by the Graph below. The graph should also eliminate any speculation that the high organ transplant rates of Spain is due to a high number of traffic victims!
**7.10.6 Pharmaceuticals**

For reasons of copyright, HCP is not in a position to include graphs showing the actual data behind the drug use indicators, only relative comparisons.

**6.1 Rx subsidy %**

What percentage of total drug sales (including OTC drugs) is paid by public subsidy? Where data from EFPIA has shown higher numbers, such as for Iceland, the score has been adjusted up from the WHO HfA values.

6.2 Layman-adapted pharmacopoeia

Is there a layman-adapted pharmacopoeia readily accessible by the public (www or widely available)? The existence of these (a comprehensive data collection on all drugs registered and offered for sale in a country, searchable both on chemical substance and brand name, and containing at least the same information as do the packing leaflets, written in a way to be understandable by non-professionals) has grown considerably from 2005, when essentially only Denmark and Sweden had them.

Today, 30 of the 35 countries of the EHCI have Internet pharmacopoeias, with patients in the remaining countries frequently able to access drug information in a language they understand from a neighbouring country.

For all these countries, the information is traceable to the package leaflet texts provided by the drug manufacturers. France and Germany (not counted among the 30 above) deviate – the information in their respective websites is every bit as comprehensive as in most countries, but it is very difficult to see who is the sender of the information. Spain used to be a real hard-core country when it came to allowing pharma companies to inform about prescription drugs direct to the public. This was probably not a big obstacle for Spanish members of the public – due to the high share of Hispanics among Americans, prescription drug information is readily available in Spanish on U.S. pharma company websites.


6.3 Novel cancer drugs deployment rate
This indicator measures the use, in MUSD p.m.p., of the ATC code group L01XC (monoclonal antibodies). The measure DDD (Defined Daily Doses) rather than monetary value would have been preferable, but unfortunately the volume data contained inconsistencies.

Sources of data: The IMS Health MIDAS database. CUTS data.

### 6.4 Access to new drugs (time to subsidy)

The indicator measures the time lag between registration of a drug, and the drug being included in the national subsidy system.

This is one indicator, where the financial crisis effects show very clearly. Even in affluent countries such as Sweden or Switzerland, there has been a significant increase in the time lag between registration of a drug, and admission of the drug into national Pharmacy Benefits Systems (drug subsidy system).


### 6.5 Deployment of arthritis medication

On drug consumption indicators (2.9 – 2.11), for copyright reasons the graphs show only relative sales (no values on the Y-axis).

The arrival of TNF-α inhibitor drugs (ATC code L04AB) meant a dramatic improvement for arthritis patients. Some countries are still restrictive on the use of these drugs, and as the graph below shows, this is not tightly correlated with GDP/capita. Drug volumes are expressed as Standard Units (an IMS Health measure, close to but not identical to DDD:s) per 1000 prevalent population ≥15 years. (DDD = Daily Defined Dose.)

6.6 Statin use
Sales per capita (SU per capita 50+ SDR adjusted). Statins, which have been on the market for almost 30 years, are the primary therapy used to prevent cardiovascular events. They lower LDL-C levels by inhibiting the enzyme HMG-CoA reductase, which has a vital role in the production of cholesterol in the liver. Statins typically reduce LDL-C levels by 30 – 40% and are directly associated with reducing the risk of heart attack and stroke. The ECHI is using actual sales data.

It is interesting to note that the straight per capita use, when NOT corrected for CVD prevalence, is more even across Europe than the prevalence-adjusted! There are (at least) two possible explanations for this:

i) Active use of these essential drugs brings down CVD mortality, resulting in higher per capita numbers in the prevalence-adjusted data.

ii) The medical profession is more affected by “kitchen wisdom” popular belief about which share of the population should receive these drugs, than governed by guidelines.

Source: IMS MIDAS database, 12 months ending June 2016. CUTS data.

6.7 Antibiotics consumption
As the following graphs will show, there is shocking disagreement between different sources regarding antibiotics consumption. The 2016 indicator is based on “Quality indicators for antibiotic consumption in Europe (1st Graph below). That was used as a CUTS.
The fact that this WHO report (based on wholesaler reports) disagrees violently with both the Eurobarometer on beliefs about antibiotics helping against viruses (2012), and with IMS Health pharmacy sales data (2013) makes the HCP team inclined to regard the WHO report, used 2014, as not trustworthy. EHCI 2016 therefore used the ECDC as data provider. The ECDC data does show the expected correlation with resistance data (indicator 3.6 above).

**Figure 1.** Consumption of antibiotics for systemic use in the community by antibiotic group in 30 EU/EEA countries, 2014 (expressed in DDD per 1 000 inhabitants and per day)

In 2012, the indicator used was "% of population who know antibiotics are *not* effective against cold and flu" (Graph below). EHCI 2013 used actual *per capita* sales of antibiotics, with the assumption that a restrictive use is good from a resistivity point of view.
The EHCI 2012 indicator.

Source: Special Eurobarometer 338, April 2010. CUTS data.

The graph below illustrates the data of the 2016 WHO report. It probably has large errors!

Antibiotics use, SU/capita 12 months ending June 2013
IMS MIDAS database

The EHCI 2013 indicator.

If the French, Brits and Belgians really do know that antibiotics do *not* work against viral infections: How come they use so much?

The graph below illustrates the data of the 2016 WHO report. It probably has large errors!
The EHCI 2014 indicator.

Source 2016: ECDC “Quality indicators for antibiotic consumption in Europe.” CUTES data.

7.11 External expert reference panel

The following persons have taken part in the Expert Reference Panel work for EHCI 2014:

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ulrik Bak Dragsted, MD, PhD</td>
<td>Head of Infectious Diseases Unit, Roskilde Hospital, Denmark &amp; President, The Danish Society of Internal Medicine</td>
</tr>
<tr>
<td>Filippos Filippidis, Dr.</td>
<td>School of Public Health, Imperial College, London</td>
</tr>
<tr>
<td>Ian Graham, Professor Dr.</td>
<td>Trinity College, Dublin</td>
</tr>
<tr>
<td>Ulrich Keil, Professor Em. Dr. Dr.</td>
<td>Institut für Epidemiologie und Sozialmedizin, Medizinische Fakultät der Westfälischen Wilhelms Universität Münster, Germany</td>
</tr>
<tr>
<td>Lennart Welin, Associate Professor Dr.</td>
<td>Lidköping Hospital, Sweden</td>
</tr>
</tbody>
</table>

As the 2016 indicator set was the same as that of 2014, and for reasons of economy, no Expert Panel meetings were held for the EHCI 2016.
8. References

8.1 Main sources

The main sources of input for the various indicators are given in Table 8.7 above. For all indicators, this information has been supplemented by interviews and discussions with healthcare officials in both the public and private sectors.

The “Single Indicator Score Sheets” are published on the Internet, so that all can see what main data have been used, and also the scoring methodology. These sheets are on www.healthpowerhouse.com/ehci2015-indicators/.

Indicators, for which data could not be converted to straightforward numbers are missing on that site. Also, for copyright reasons, so is numerical data for indicators based on drug sales numbers, which are illustrated in a Powerpoint presentation on the website.
Appendix 1. The True Saga About Werner’s Hip Joint, or What Waiting Times Should Be In Any Healthcare System

This is a true story, which happened in July 2013 in a small town of 8000 (winter) inhabitants in Languedoc, 50 km south of Montpellier. Werner, (not his real name) is a German military man who has retired with his wife to the south of France. The services described below were paid for by Werner’s normal German health insurance with no private top-up. Here goes:

Like most expats in the little town, Werner was sitting on a Tuesday afternoon outside the Marine Bar taking a refreshment. Werner tells his wife:

- Helga, dear, I believe I should have somebody look at my left leg. I have been having these pains for a year and a half now.
- Werner, dear, that door across the street has a brass plate on it. It looks just like a doctor’s surgery!

Werner limps across the street and finds that the brass plate adorns the door of the surgery of Dr. B, a local GP. Werner rings the bell, and explains his problem to the nurse/secretary opening.

- Could Dr. B possibly have a look at my problem?
- Not right now, but please come back in half an hour!

Werner limps back across the street, finishes his beer, and goes to see Dr. B. Dr. B examines Werner and says:

- I am afraid that this looks as if you might need a new hip joint. We will have to take a closer look. Are you doing anything special tomorrow?
- No, I am retired, so I am very flexible.

Dr. B picks up his phone, speaks for a couple of minutes, puts the receiver down and says to Werner:

- You are booked for a CT scan tomorrow morning at 10:00 in Agde Radiology Centre (7 km away). After that, come and see me again on Thursday at 3 pm! We should have the results by then.

Werner goes and has the CT scan and reappears at Dr. B:s on the Thursday. Dr. B says:

- I am afraid it seems that my first diagnosis was correct. You need your hip joint replaced. Are you doing anything special next week?
- No, I am retired, so I am very flexible.

Dr. B picks up the phone again, speaks for a few minutes and turns back to Werner.

- You are expected in the Orthopaedic Clinic of the University Hospital of Montpellier19 at 09:00 on Monday. Bring a small overnight bag with your necessities for a four-day stay!

On the following Friday, Werner is discharged from the hospital, spick and span with a new hip joint. Calendar time for the entire sequence of events: 10 days!

The important morale of the story: The big part of healthcare costs is always man-hours put in by healthcare staff. The 10-day procedure above has precious little room for man-hours at all. That is why it is cheaper to operate a healthcare system without waiting lists, than to have waiting lists!

19 The oldest medical faculty in Europe. The 6th best hospital in France, according to a recent ranking.